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Angiogenesis, the formation of new blood vasculature from pre-existing vessels, is a hallmark of 
cancer. The extracellular matrix (ECM) molecule, MULTIMERIN2 (MMRN2), is specifically 
deposited along the vasculature in tight juxtaposition with endothelial cells (ECs). We have 
previously demonstrated that the glycoprotein halts ECs’ motility and impairs tumor angiogenesis 
through the interaction with VEGF-A165, leading to the down-regulation of VEGF-A/VEGFR2 
signaling axis. In this study, we identified the region of the MMRN2 responsible for the binding, 
demonstrating that the interaction involves the carbohydrate chains. We have also found that 
MMRN2 interacts with other VEGF-A isoforms and VEGF family members suggesting that the 
molecule may function as a reservoir for different cytokines. Moreover, we demonstrated that the 
anti-migratory function of the molecule hinges on a reduced VEGFR2 phosphorylation at both 
Y1175 and Y1214, which leads to the down-modulation of SAPK2/p38 activation. Furthermore, we 
found that MMRN2 impaired VEGFR2 function by reducing its availability at the ECs’ plasma 
membrane.  
Through in vitro and in vivo tests we demonstrated the angiostatic role of MMRN2 and its active 
fragment and, as a consequence, the over-expression of the molecule or its active deletion mutant 
by cancer cells led to a dramatic reduction of tumor growth.  
Given its strategic localization, we have recently hypothesized that MMRN2 may represent a 
homeostatic molecule buffering the angiogenic stimuli and maintaining the endothelium quiescent. 
In line with this hypothesis MMRN2 is deposited over time during vessel maturation and the co-
culture of ECs with pericytes boosts its secretion and organization. In addition, we have 
demonstrated that MMRN2 represents an adhesion substrate for pericytes and may be required for 
their recruitment, since pericyte coverage of the MMRN2 knockout retinal vessels is strongly 
impaired. We also found that the down-modulation of MMRN2 leads to an increased vascular 
permeability associated with an impaired expression of the tight junction-associated molecules 
occludin and ZO-1. Accordingly, preliminary data show that the MMRN2 knockout mice displayed 
an increased vascular leakage. Taken together these results pinpoint MMRN2 as a key angiostatic 
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Ad MMRN2: Adenovirus MMRN2 
AJ: Adherens Junctions 
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CLDN: Claudins 
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EC: Endothelial Cell 
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MMPs: Matrix Metalloproteases 
PBS: Phosphate Buffered Saline 
PDGF: placental-derived growth factor  
siRNA: Small Interfering RNA 
TGF-β: Trasforming Growth Factor-beta 
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3.1  Angiogenesis. 
Blood vessel formation is regulated by two fundamental processes termed vasculogenesis and 
angiogenesis (Carmeliet P., 2000; Risau W., 1997; Risau and Flamme., 1995). Vasculogenesis is 
defined as the differentiation of precursor cells (angioblasts) into endothelial cells (ECs) and the de 
novo formation of a primitive vascular network. On the contrary, angiogenesis is the formation of 
new capillaries from pre-existing vasculature. In the embryo, blood vessels form through both 
vasculogenesis and angiogenesis. Whereas, in the adult, the angiogenetic process occurs only in 
particular conditions such as wound healing, menstrual cycle as well as in various ischemic and 
inflammatory diseases to allow the maintenance of physiological homeostasis (Carmeliet P., 2003).  
Blood vessels are a complex network of tubes that transport oxygenated blood and nutrient 
throughout the body and are composed of different interacting cell types. In particular, ECs line the 
inner side of the vessel wall, and mural perivascular cells which envelop the surface of the vascular 
tube and include pericytes and vascular smooth muscle cells. Pericytes have an important role in 
maintaining vascular homeostasis and when vessels lose their coverage they become hemorrhagic 
and hyperdilated. This condition can lead to edema, diabetic retinopathy, and even embryonic 
lethality (Bergers G. and Song S.,2005).  
Normal angiogenesis relies on a proper interaction between ECs, pericytes and surrounding cells 
and their association with extracellular matrix (ECM) components, including the constituents of the 
vascular basement membrane (BM). The BM divides the ECs from the surrounding connective 
tissue and is mostly composed of laminins, collagen and proteoglycans (Lebleu V.L. et al., 2007).  
 
The angiogenic process takes place through the engagement of multiple steps (Fig. 1): 
 
1) Production of angiogenic growth factors (such as vascular endothelial growth factor, VEGF-A) 
and the binding to their receptors on the ECs surface that leads to the activation of specific signaling 
pathways; 
 
2) Release of proteases, including matrix metalloproteases (MMPs), by ECs which lead to ECM 
degradation and support and guidance ECs migration; 
 
3) Proliferation of ECs that leads the formation of capillary sprouts; 
 
4) Migration of ECs towards the angiogenic stimulus; 
 
5) Tube formation with an encased lumen sealed by tight cell-cell junctions, synthesis of BM 
proteins and assembly of a new BM; 
 
6) Anastomosis, the process through which the capillaries emanating from the arterioles and the 
venules come together and allow the flow of blood within the mature vessel. 
Introduction 
 




Fig. 1: Scheme of the sequential steps characterizing angiogenesis. Six critical steps occuring during this 
tightly regulated process have been identified and described. 
 
 
3.2  The endothelial barrier. 
The endothelium, a tight monolayer of ECs, acts as a dynamic barrier that allows the passage of 
fluids, electrolytes and proteins from the blood into the adjacent tissues. The integrity of this barrier 
is crucial for the maintainance of the circulatory homeostasis and the physiological functions of the 
various organs. The passage of macromolecules, fluids and cells through this barrier can occur via 
either the transcellular or the paracellular pathways (Gavard J., 2009). The first pathway is 
responsible for the transport of small molecules (inferior to 3 nm), such as albumin, which involves 
a system of trafficking vesicles, called vesicular vacuolar organelles. On the contrary, cells and 
molecules larger than 3nm are transported through the paracellular pathway, which occurs for 
instance during the trans-endothelial migration of leukocytes and metastatic cells. The paracellular 
permeability is dependent on a coordinated aperture and closure of endothelial cell-cell junctions.  
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In the endothelium, the junctional complexes comprise adherens junctions (AJ), tight junctions (TJ) 
and gap junctions (Fig. 2). Gap junctions, formed of connexins, allow the passage of water and ions 
but they are not involved in the regulation of the vascular barrier. AJs are found in all microvascular 
beds, and are the most ubiquitous type of endothelial cell–cell junctions. Among different AJ 
molecules, one of the most important is the vascular endothelial cadherin (VE-cadherin), which is 
exclusively expressed by ECs (Dejana E., 2004). The deletion of the VE-cadherin gene in mice 
leads to early embryonic lethality due to substantial vascular defects, whereas loss of its function 
induces hyperpermeability in adult mice (Carmeliet P. et al., 1999; Crosby CV. et al., 2005).  
TJ consist of several transmembrane or membrane-associated proteins including the membrane 
spanning claudins (CLDN), occludin (OCLN) and the JAM family of junctional adhesion molecules 
(Dejana E., 2004). OCLN and CLDN are integral membrane proteins, each with four 
transmembrane domains and two extracellular loops. OCLN is expressed at high levels, with a 
continuous distribution along the ECs of the brain and at much lower levels and with a 
discontinuous pattern in ECs of other tissues (Hirase T. et al., 1997).  
The TJ are connected to the actin cytoskeleton via adaptor proteins such as ZO-1, ZO-2, ZO-3, 




Fig. 2: Schematic overview of the adherens and tight junctions. α, α-catenin; AF6, afadin/AF6; AJ, 
adherens junctions; β, β-catenin; JAMs, junctional adhesion molecules; p120, p120catenin; TJ, tight 
junction; ZO, zona occludens. 
 
 
The endothelium and its junctions play a critical role in regulating vascular functions during both 
pathological and physiological processes. Dysregulation of cell junctions and a significant increase 
in vascular permeability can lead to pathological situations including inflammation, trauma, 
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Vascular permeability involves the coordinated regulation of multiple signaling pathways in the 
ECs (Aghajanian A. et al., 2008), thus, the identification of the most mechanisms regulating this 
process open the possibility to develop new targets for therapeutic treatment or new prognostic 
markers in many pathological disease where vascular permeability is adversely affected.  
3.3  Vascular endothelial growth factors. 
Among the many factors implicated in angiogenesis, VEGF has been identified as one of the most 
important players in vascular EC growth, survival, and permeability. The VEGF family comprises 
seven members including placental-derived growth factor (PDGF), VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, VEGF-E, VEGF-F, encoded by multiple exons that can give rise to different isoforms 
after alternative splicing. The inclusion or exclusion of exons can have important consequences in 
the regulation of angiogenesis, since the variants are characterized by different solubility and 
affinity for receptor binding (Sullivan and Brekken., 2010). 
In particular, VEGF-A can be generated in four major homodimeric isoforms VEGF121, VEGF165, 
VEGF189, and VEGF206. All these isoforms, except VEGF121, bind to heparin and therefore are in 
close association with the ECM. Also VEGF-B is present in two isoforms constituted by 167 and 
186 amino acid residues. Little is known about alternative splicing of human VEGF-C and VEGF-
D, although multiple isoforms of mouse VEGF-D have been described (Baldwin ME. Et al., 2001).  
VEGF is produced by several cell types, such as tumor cells (Aonuma M. et al., 1999), muscle 
(Bryan BA. et al., 2008) and neuronal cells (Jin et al., 2006), but its actions is mainly associated to 
ECs.  
Following a hypoxic stimulus, VEGF binds to VEGFR-1 (Flt-1), VEGFR-2 (Flk1/KDR), and 
VEGFR-3 (Flt4), three membrane tyrosine kinase receptors mainly expressed by blood vessel ECs 
and lymphatic ECs (Koch S. and Claesson-Welsh L. et al., 2012). Although with different 
biological activities, all VEGFRs play an important role in angiogenesis. In fact, the knockout of 
VEGFR-1, VEGFR-2, and VEGFR-3 leads to embryonic lethality in mice as a result of severe 
vascular defects (Goishi K. et al., 2004). Interestingly, the VEGFR2 receptor, characterized by a 
strong kinase activity, is the predominant mediator of VEGF-induced angiogenic signaling, despite 
having a lower affinity for VEGF if compared to VEGFR1. Probably due to its strong activity, 
VEGFR-2 is also the major responsible for hyperpermeability induced by VEGF. Some evidences 
have been generated indicating that VEGFR-1 also plays a role in endothelial permeability but the 
contribution of the receptor appears to be minor compared to that of VEGFR2.  
Once VEGF binds VEGFR2, it induces receptor homo- or heterodimerization and its auto-
phosphorylation. The major phosphorylation sites on VEGFR2 occur on tyrosines 1175 and 1214 
inducing the activation of signaling cascades through PI3K, AKT, PLCγ, p38 MAPK and p42/44 
MAPK, which in turn regulate EC survival, migration, proliferation and vascular permeability 








Fig 4: VEGFR2 phosphorylation sites and signal transduction. Schematic representation of the 
intracellular domains of dimerized and activated VEGFR2; the different tyrosine-phosphorylation sites that 
are indicated by the amino acid residue’s numbers. The position of the tyrosine residues within the receptor 
are indicated by dark blue squares. The signaling molecules (dark blue ovals) binding to specific 
phosphorylation sites (boxed numbers) initiate signaling cascades (light blue ovals), which leads to the 
establishment of specific biological responses (pale blue boxes). Dashed arrows indicate that the signal 
initiation is not certain. The biological responses are highlighted by pink boxes (Olsson A.K. et al., 2006). 
 
 
3.4  Tumor angiogenesis. 
Angiogenesis is governed by a finely tuned balance between pro-angiogenic factors, that induce the 
formation of blood vessels, and anti-angiogenic-factors, which inhibit the process. Once this 
balance is jeopardized it leads to the formation of structurally defective vessels. This occurs for 
instance during tumor formation, where the over-production of growth factors leads to the 
development of numerous dysmorphic vessels that allow tumor growth and metastasis. Tumor 
formation begins with an avascular mass with an intrinsic tumorigenic potential that alone is not 
sufficient to support tumor activation (Papetti M. et al., 2002).  
These small lesions, of not more than 1-2 mm in diameter linger in a steady dormant state (Folkman 
J., 1971) and only few became exponentially growing vascularized tumors (Fig. 5).  
The accumulation of genetic alterations empowers some neoplastic cells with the ability to secrete 
large amounts of pro-angiogenic factors such as VEGF and/or suppress the expression of anti-
angiogenic molecules like transforming growth factor-beta, TGF-β. In turn, this leads to a 
dismantled local balance between activators and inhibitors of angiogenesis and the pro-agiogenic 
factors take over giving rise to the process called the "angiogenic switch" (Hanahan D. et al., 1996). 
Following secretion, the pro-angiogenic factors diffuse through the tissue and activate the ECs 
adjacent to the tumor.  
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These cells lose the tight contacts with neighbouring cells (Papetti M.et al., 2002) and secrete 
proteolytic enzymes and proteases to degrade BM and ECM, allowing their migration into the 
perivascular space towards angiogenic stimuli (Pepper M.S., 2001). Following extravasation, the 
ECs continue to secrete proteolytic enzymes, which also degrade the ECM. This is necessary to 
create a pathway along which the cells can move and also allows the release of growth factors that 
are normally sequestered by the matrix, thus further boosting the angiogenic signals (Hirschi K. K. 
et al., 1996). ECs continue to move forming small sprouts which elongate through the recruitment 
of additional ECs from the parent vessel. These sprouts take the form of solid strands of cells and 
ECs subsequently form a central lumen, thereby creating the necessary structure for a new blood 
vessel. Differently from normal vasculature, which is characterized by a hierarchical organization 
into arteries, arterioles, capillaries, venules and veins, the vessels associated with solid tumors are 
characterized by a number of prominent abnormalities. Frequent aberrations are the presence of 
dilated blood vessels, vessels with areas containing absent or abnormal BM, vessels having extreme 
tortuosities, the lack of supporting perivascular cellular elements such as pericytes, or abnormalities 
in the pericyte population and excessive vascular leakiness (Carmeliet P. et al., 1996). 
Consequently, blood flow and perfusion within tumors can be highly altered with some areas 
deprivated of oxygen and nutrients leading to the formation of hypoxic ischemic regions and to 
tumor cell necrosis (Nagy JA. et al., 2009).  
 
Fig. 5: The classical angiogenic switch. Schematic representation of the different processes occurring in the 
tumor-progression pathway (Bergers G. and  Benjamin LE., 2003). The tumoral mass starts growing as an 
avascular dormant nodule (a) until it reaches a steady-state level where the number of proliferating cells is 
balanced by those undergoing apoptosis. The angiogenic switch, necessary to ensure exponential tumor 
growth, begins with perivascular detachment and vessel dilation (b), followed by angiogenic sprouting (c), 
new vessel formation and maturation, and the recruitment of perivascular cells (d). Blood-vessel formation 
will continue as long as the tumour grows (e). 
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VEGF-A not only plays a central role in normal angiogenesis but also in tumor-associated 
angiogenesis. The growth factor and its receptor VEGFR2 are in fact upregulated in many cancers 
including breast cancer (Kurebayashi J. et al., 1999), colon cancer (Shaheen RM. et al., 1999), 
hepatoma (Yoshiji H. et al., 1999), gastric cancer (Kitamura M. et al., 1998) and prostate cancer 
(Balbay MD. et al., 1999). In addition, a high expression of VEGF correlates with invasiveness, 
vascular density, appearance of metastasis, and poor prognosis (Seo Y. et al., 2000). Due to its 
pleiotropic effects, several strategies to target VEGF or its receptor have been attempted and are 
currently under development. These include monoclonal antibodies directed against VEGF or 
VEGFR, soluble VEGFR/VEGFR hybrids, and a variety of small-molecule VEGFR tyrosine kinase 
inhibitors. Although these agents have often been proved efficacious in pre-clinical experimental 
settings, results in human cancer have been less impressive, probably due to the heterogeneity of the 
tumor vasculature (Ebos JM. et al., 2009; Carmeliet P. and Jain RK., 2011; Cascone T. and 
Heymach JV., 2012; Ferrara N., 2005). An emerging alternative to ameliorate the therapeutic 
outcome, avoid resistance and improve chemotherapic and radiotherapic treatments is possibility to 
readdress the aberrant tortuous and leaky vessels associated with tumours towards a normalized 
more efficient vasculature (Sorensen AG. et al., 2012; Emblem KE. et al., 2013; Jain RK. 2014; 
Wong PP. et al., 2015). 
 
 
3.5  The extracellular matrix. 
The extracellular matrix (ECM) is an intricate network of non-cellular components, made by 
proteins and water-absorbing polysaccharides in which the cells of the microenvironment are 
embedded (Bissell M.J. et al., 2005). It is present in all tissues and organs and provides not only 
physical scaffolding for the cellular components, but also activates the biochemical and mechanical 
signals required for tissue morphogenesis, differentiation and homeostasis. These effects are further 
amplified by the intrinsic property of the ECM molecules to function as reservoirs of growth 
factors, cytokines, matrix metalloproteinases and processing enzymes (Sternlicht M.D.et al., 2001). 
The relative availability of these elements increases once the ECM rearranges and it is 
enzymatically processed during wound healing or tumor progression. The ECM is a highly dynamic 
structure undergoing continuous remodelling, which consists in the deposition, degradation, and 
modification of its components. Two main classes of macromolecules compose the ECM: 
glycosaminoglycans (GAGs) and fibrous proteins which include collagen, elastin, fibronectin, and 
laminin. These proteins are majorly produced by fibroblasts as precursor molecules and then are 
incorporated into the ECM in accordance with the needs of the tissues.  
Collagen is the most abundant protein in the human body, it provides tensile strength, regulates cell 
adhesion, supports chemotaxis and migration, and directs tissue development (Rozario T. and 
DeSimone DW., 2010). Collagen is associated with elastin, a flexible protein that allows tissues to 
return to their original shape following a stretch. Fibronectin, another fibrous protein, is an 
important substrate for cell migration but it was also demonstrated to regulate cell division.  
The importance of  ECM proteins is highlighted by the fact that a wide variety of human syndromes 
are caused by mutations in the genes encoding for this type of proteins (Jarvelainen et al., 2009). 
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Not only the fibrous ECM proteins play a structural and also functional role in regulating cell 
function, but also some members have been demonstrated to exert an active part in the regulation of 
angiogenesis. In particular, Collagen IV (Mammoto T. et al., 2013), and laminin (Simon-Assmann 
P. et al., 2011), provide structural support for ECs and blood vessel formation thanks to the 
adhesive interactions occurring with the EC surface integrin receptors. Thus, through the 
engagement of the integrins and also by different mechanisms, the ECM affects many fundamental 
aspects of the EC biology, including proliferation, migration, morphogenesis, survival, as well as 
blood vessel development and stabilization (Ingber DE. Folkman J., 1989; Neve A. et al., 2014; 
Senger DR, Davis GE., 2011; Cheresh DA, Stupack DG., 2008). Other ECM molecules that have 
been shown to affect angiogenesis are fibronectin (Yi M. Ruoslahti E., 2001), vitronectin (Li R. et 
al., 2014), , thrombospondins (Lawler PR, Lawler J., 2012), SPARC (Jendraschak E, Helene Sage 
E., 1996), perlecan (Aviezer D. et al., 1994) and decorin (Jarvelainen H. et al., 2015). To further 
complicate this scenario, ECM proteolytic fragments can also affect angiogenesis, often exerting 
opposite effects compared to the intact molecule of origin. The degradation and liberation of matrix 
fragments is regulated by specific proteinases produced by ECs following angiogenic stimulus, 
which include the plasminogen activator (PA)/plasmin system and matrix metalloproteinases 
(MMPs). The first is an enzymatic cascade involved in the control of fibrin degradation, matrix 
turnover, and cell invasion. On the contrary, MMPs belonging to the family of zinc endopeptidases, 
can exist in both soluble and membrane-bound (MT-MMPs) forms. These proteases are produced 
by many cells, including epithelial cells, fibroblasts, inflammatory cells, and ECs. At least, five 
MMPs have a role in angiogenesis: MMP1, MMP2, MMP3, MMP7, and MMP9, often upregulated 
in ECs in physiological and pathological conditions (Davis GE. et al., 2001).  
 
 
3.6  The EMILIN protein family. 
EMILINs are a family of ECM glycoproteins characterized by the presence of a cysteine-rich EMI 
domain at the N-terminus. Moreover, most of these members also display a gC1q-like domain at the 
C-terminus (Doliana R. et al., 2000; Mongiat M. et al., 2000). These glycoproteins can be clustered 
into three groups: 
 The first group (Fig. 6) includes EMILIN1 (Doliana R. et al., 2000), EMILIN2 (Doliana R. 
et al., 2000), MULTIMERIN1 (Hayward C.P. et al., 1991) and MULTIMERIN2 (Christian 
S. et al.,2001) 
 The second group is composed by only one gene named EMILIN3. The protein has a 
structure similar to that of the previous group except for the lack of the gC1q domain 
(Leimeister C. et al., 2002). As recently reported, the protein is able to function as an 
extracellular regulator of the activity of TGF-β ligands (Schiavinato A. et al., 2012). 
 The last group includes two genes, Emu1 and Emu2, which unlike the other groups, present 
only the EMI domain at the N-terminus. These two proteins display a completely different 
structure compared to the other members given that most of their sequence is collagenous 
(Leimeister C. et al., 2002) 
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Fig. 6: Graphical representation of EMILIN/Multimerin family members.(EMI) EMI domain; Coiled-
coil region; (C1q) gC1q-like domain; (PR) prolin-rich domain; (RR) arginine-rich domain; (EG) region with 
partial similarity with EGF domain (Colombatti A. et al., 2011). 
 
 
3.6.1  EMILIN1. 
EMILIN1, the archetype protein of the family, was originally identified during the isolation of 
elastic-specific glycoproteins. EMILIN1, a protein of 115 kDa is specifically localized at the 
interface between the amorphous elastin surface and microfibrils, hence the acronym (Elastin 
Microfibril Interface Located proteIN) (Bressan G. et al., 1993). The protein, it is highly expressed 
at the level of large blood vessel wall and in the connective tissue of a wide array of organs 
(Colombatti A. et al., 1985). During mouse development, EMILIN1 mRNA is expressed along the 
blood vessels and perineural mesenchyme (Braghetta P. et al., 2002). In addition, intense labeling is 
identified in the mesenchyme of many organs including lung and liver and in different 
mesenchymal condensations such as limb bud and branchial arches. At late gestation stages 
EMILIN1 staining is widely distributed in the interstitial connective tissue and in smooth muscle 
cell-rich tissues. After birth, the EMILIN1 mRNA expression levels decline with the age increase. 
EMILIN1 displays different functions: 
 It has adhesive and migratory properties for different cell types. It is a ligand for the α4β1 
integrin and the interaction occurs through the gC1q1 domain (Spessotto P. et al.,2003).  
 It is also highly expressed along the lymphatic vessels regulating both their structure and 
function (Danussi C. et al., 2008). In fact, EMILIN1 deficiency results in hyperplasia and 
enlargement of the superficial and visceral lymphatic vessels, which often display an 
irregular pattern.  
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 EMILIN1 deficiency also leads to a significant reduction of the anchoring filaments, and 
this correlates with the functional defects observed, such as mild lymphedema, an enhanced 
lymph leakage and a significant decrease of lymph drainage. EMILIN1-deficient mice also 
develop larger lymphangiomas if compared to wild type mice (Danussi C. et al., 2008). 
Moreover, EMILIN1 deficiency causes skin and lymphatic vessel hyperplasia and structural 
anomalies in lymphatic vasculature. Furthermore, an EMILIN1-negative microenvironment 
promotes tumor cell proliferation as well as the dissemination of cancer cells to the lymph 
nodes (Danussi C. et al., 2012). 
 
 
3.6.2  EMILIN2.  
EMILIN2 was cloned following a two-yeast hybrid screening using the globular gC1q domain as a 
bait (Doliana R. et al., 2001). This protein is characterized by a proline-rich (41 %) segment of 56 
residues between the coiled-coil region and the collagenous stalk. Differently from EMILIN1, 
EMILIN2 displays a low expression in adult aorta, small intestine and appendix, whereas the 
highest levels of the protein can be detected in fetal heart and adult lung mice.  
In mouse embryos, EMILIN2 mRNA expression is more restricted compared with that of 
EMILIN1; early expression includes somites, neural tube and mesenchyme of branchial arches, 
limb buds, intervertebral disks and perineural tissue. Weak staining is also found in mesenchymal 
cells of most organs, including lung, liver, intestine and bladder at the beginning of organogenesis. 
The strongest EMILIN2 expression was detected in the heart, starting at E8.5 and reaching the 
highest levels at E11.5. Labelling is restricted to the myocardium, while the endocardium is 
negative. Unlike other members of the family, staining for EMILIN2 was also detected in the 
central nervous system. In the adult tissues, EMILIN2 mRNA expression is mostly evident in the 
spleen and the uterus whereas it is weak in kidney and gut (Braghetta P. et al., 2004). Moreover, 
EMILIN2 was found to be one of the major basilar membrane components in the cochlea (Amma 
L.L. et al., 2003). At the functional level, EMILIN2 was demonstrated to significantly impair tumor 
growth inducing tumor cell apoptotic death. EMILIN2 adopts a totally different mechanism from 
other ECM proteins that promote cell death; in fact, it bears the unique property to directly interact 
with and activate death receptors, in particular DR4. The activation of the extrinsic apoptotic 
pathway leads to a dramatic decrease of tumor cell viability and to anti-tumorigenic properties as 
demonstrated by in vitro and in vivo studies (Mongiat M. et al., 2007). Moreover, we have recently 
demonstrated that EMILIN2 exerts an additional anti-proliferative function in the tumor 
microenvironment. In fact, we have shown that EMILIN2 targets directly breast cancer cells 
impairing their growth and motility by negatively modulating Wnt signaling activation (Marastoni 
S. et al., 2014). Interestingly and unexpectedly, EMILIN-2 also stimulates the development of new 
vessels (Mongiat M. et al., 2010; Broniz A. et al., 2012). The molecular mechanisms by which 
EMILIN2 could affect ECs behavior and activate angiogenesis were until now unknown, but they 
have been recently highlighted by our research group and submitted for a publication. Briefly, we 
found that EMILIN2 produced by fibroblasts induces the activation of EGFR at the EC surface 
following both a direct binding to the receptor and its ligand EGF. This leads to the activation of the 
Jak2/STAT3 pathway, IL8 production and a consequent increase of EC proliferation and migration. 
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In addition, this mechanism is elicited also fibroblasts, thus EMILIN-2 induces the activation both 
through autocrine and paracrine mechanisms (Fig. 7). The molecular activations prompted by 
EMILIN-2 were further assessed in various ex vivo and in vivo experimental settings. In particular, 
employing a syngenic melanoma cell line in wild-type and Emilin-2 knock-out mice, we 
demonstrated that EMILIN-2 deficiency compromised the intratumoral vascularisation and this was 
associated with a strong reduction of the tumor growth. Interestingly, we also found that in tumors 
from wild type mice the vessels are more numerous compared to those grown in Emilin-2
-/-
 mice, 
they display an intact basal lamina and are also better perfused and more efficient in transporting 




Fig. 7: EMILIN2 activates IL-8 production in ECs and fibroblasts. Schematic representation of the 
effects of fibroblast- derived EMILIN2 on ECs. EMILIN2 binds to the EGFR thus inducing IL 8 production. 
As a consequence IL8 activates ECs affecting both their proliferation rate and their motility. Moreover, 
EMILIN2 induces IL8 expression also in fibroblasts  thus acting both in a paracrine and autocrine fashion.  
 
 
3.6.3  MULTIMERIN1.  
MULTIMERIN1 (MMRN1) is a soluble S–S linked homopolymer stored in platelets, 
megakaryocytes and ECs (Hayward C.P., 1997; Adam F. et al., 2005). It supports the adhesion of 
platelets, neutrophils, and ECs via integrin αvβ3 and αIIbβ3 (Adam F. et al., 2005). MMRN1 binds 
to collagen and it is able to enhance von Willebrand factor-dependent platelet adhesion to collagen, 
thus supporting thrombus formation. MMRN1 has a high affinity for factor V (Jeimi S.B. et al., 
2008) and this facilitates the co-storage in platelet α-granules. During platelet activation, MMRN1 
is released from platelets, it regulates thrombin production, thus halting thrombus formation. 
MMRN1 prompts cell adhesion through the RGD sequence present at the N-terminus of the 
molecule; on the contrary no other domain or motif within the molecule has been held responsible 
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3.6.4  MULTIMERIN2. 
MULTIMERIN2 (MMRN2) also known as EndoGlyx-1, was identified during a screening for new 
antigenic markers of the vascular endothelium, using the monoclonal antibody H572 raised against 
the human umbilical vein EC (Sanz-Moncasi MP. et al., 1994) (Fig. 8). Unlike other members of 
the family, MMRN2 is characterized by a short cluster of charged amino acids (10 out of 27 
residues) located between the coiled-coil region and the C1q-like domain.  
The basic amino acids are arranged in a sequence similar to that of the consensus motifs responsible 
for the ionic interactions with glucosaminoglycans, such as heparin and heparan sulfate (Hileman 
RE. et al., 1998) and are also found in heparin binding proteins like the von Willebrand factor 
(Sobel M. et al., 1992). In an extensive immunohistochemical survey of normal human fetal and 
adult tissues as well as human cancer tissues, MMRN2 was found to be exclusively expressed at the 
blood vessel endothelium level. Notably, these include capillaries, veins, arterioles, and muscular 
arteries. Interestingly, no immunoreactivity was observed in the sinusoidal endothelial cells of the 
spleen and liver. In neoplastic tissues, MMRN2 was consistently found to be deposited along tumor 
capillaries and, in certain tumors, in the “hot spots” of neoangiogenesis (Sanz-Moncasi MP. et al., 
1994). The staining pattern revealed a uniform cell surface and cytoplasmic distribution of the 




Fig. 8: Immunohistochemical staining of MMRN2 on human blood vessels. Sections of normal breast 
tissue stained with the H572 mAb detecting MMRN2 or with TEA-1 mAb detecting VE-Cadherin (Christian 
S. et al., 2001). 
 
 
Quite recently, we have demonstrated that once over-expressed, MMRN2 halts the development of 
new blood vessels and induces a strong inhibition of tumor growth (Lorenzon E. et al., 2012). The 
molecule plays an important role in the regulation of EC behavior negatively affecting EC motility 
and inducing a significant impairment of angiogenesis. In our study, we identified the molecular 
mechanism responsible of these effects which rely, at least in part, on the binding of VEGF-A to 
MMRN2. A more in-depth analysis on the anti-angiogenic effect of MMRN2, the identification of 
the active region of the molecule responsible of this effect as well as the investigation of the 
putative role of MMRN2 in the regulation of EC homeostasis have been the subject of my PhD 















4.  AIMS OF STUDY 
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The ECM molecule MULTIMERIN2 (MMRN2), secreted by ECs and deposited along the 
vasculature in tight juxtaposition with these cells, is a strong inhibitor of angiogenesis. In our 
laboratory we have previously demonstrated that the over-expression of this molecule affects ECs’ 
behavior inducing a strong reduction of their motility. This effect is due, at least in part, to a direct 
binding of MMRN2 to VEGF-A165, which in turn results in a significant inhibition of the VEGF-
A/VEGFR2 signaling axis. Moreover, we have found that the angiostatic effects induced by the 
over-expression of MMRN2 lead to an impressive impairment of tumor growth and a strong 
decrease of the density of the tumor-associated vessels. Starting from these promising evidences we 
thought to better elucidate the role of MMRN2 in this context and in particular to:   
1) Identify the region of MMRN2 involved in the interaction to VEGF-A165 and responsible for its 
anti-angiogenic effect. Moreover we intended to investigate if this interaction is mediated by 
oligosaccharides or by the protein core of the molecule. In addition, we were interested to verify if 
MMRN2 or its putative active fragment bound to other VEGF-A isoforms and/or other VEGF 
family members involved in angiogenesis.  
 
2) Assess if MMRN2, given its strategic deposition along the vessels could be an important 















5.  MATERIALS AND METHODS 
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5.1  Cell cultures. 
Human Umbilical Vein Endothelial Cells (HUVEC) were isolated from the human umbilical cord 
vein as previously described (Jaffe EA et al., 1973). Cells were cultured in M199 medium (GIBCO, 
Invitrogen, Milan, Italy) supplemented with 20% fetal bovine serum (FBS) (GIBCO, Invitrogen, 
Milan, Italy), 1% Penicillin-Streptomycin (Sigma-Aldrich, Milan, Italy), 50 mg/ml heparin (Sigma-
Aldrich, Milan, Italy) and bovine brain extract (0,5%). Embryonic kidney 293-EBNA (Epstein-Barr 
Nuclear Antigen) cells were a gift from Rupert Timpl (Max Planck, Munich, Germany) and were 
cultured in Dulbecco’s modified Eagle medium (DMEM) (Sigma-Aldrich, Milan, Italy) containing 
10% FBS, 1% Penicillin-Streptomycin and 250 µg/ml of G418 (Sigma-Aldrich, Milan, Italy); 0.5 
µg/ml of puromycin (Sigma-Aldrich, Milan, Italy) were added after transfection. The human 
fibrosarcoma (HT1080) cell line was obtained from American Type Culture Collection (ATCC, 
Manassas, VA) and cultured in DMEM containing 10% FBS, 1% Penicillin-Streptomycin and 600 
µg/ml of G418 after transfection. Normal human dermal fibroblast (NHDF) cells were obtained 
from LONZA (Basel, Switzerland) and maintained in DMEN supplemented with 10% FBS and 1% 
Penicillin-Streptomycin. All cells were maintained at 37°C in a humidified 5% CO2 atmosphere.  
5.2  Antibodies and other reagents. 
The anti-histidine antibody was from Abgent (San Diego, CA, USA), the Ni-NTA agarose was 
from QIAGEN (Milan, Italy). The anti-MMRN2 polyclonal antibody was obtained upon 
immunization of a rabbit with 150 µg of a recombinant MMRN2 fragment corresponding to the N-
terminal gC1q domain. The antibody was affinity purified from the rabbit serum by means of the 
CNBr-activated Sepharose 4B resin (Amersham, GE-Healthcare, Milan, Italy). The secondary horse 
radish peroxidase (hrp)-conjugated antibodies were from Amersham (GE-Healthcare, Milan, Italy). 
The secondary antibodies conjugated with Alexa Fluor 488, 568 and TO-PRO-3 were from 
Invitrogen (Milan, Italy). Recombinant human VEGF-A165, VEGF-A145,  VEGF-A189 proteins were 
from R&D systems, Inc (MN,USA) and VEGF121 from Peprotech (London, UK). The basic FGF, 
VEGF-B167 was from Peprotech (Rocky Hill, NJ). The anti-SMA was from Abcam (Cambridge, 
UK). The anti-CD31 antibody and Matrigel were from BD Biosciences. The anti-VEGFR2 and anti 
phospho-VEGFR2 (Tyr1175) and (Tyr1214), the anti-p38 and anti-phospho-p38, and the anti-β-
actin and the anti-VE-cadherin antibodies were from Cell Signaling Technology Inc. (Danvers, MA, 
USA). The anti-ZO-1 and the anti-occludin antibodies were from Invitrogen (Life Technologies 
Italia, Monza, Italy) The anti-VEGF-A antibody was from Sigma-Aldrich (Milan, Italy). Anti-
VEGF-B, anti-VEGF-C, anti-VEGF-D and anti-PlGF were from Santa Cruz Biotechology Inc. 
(California, USA). The in situ Cell Death Detection Fluorescein Kit was purchased from Roche 
Diagnostics S.p.a. (Milan, Italy). Cytodex 3 microcarriers were from GE Healthcare Life Sciences 
(Milan, Italy). Drabkin reagent kit and Tunicamycin and FITC-dextran (70kDa) were purchased 
from Sigma-Aldrich (Milan, Italy); AngioSense
®
 750EX fluorescent imaging agent was from 
PerkinElmer (Waltham, Massachusetts). HBVP (Human Brain Vascular Pericytes) cell lines was 
obtained from SciencCell (Carlsband, CA, USA) 
 
Materials and methods 
 
 
- 25 - 
 
5.3  DNA constucts. 
The following MMRN2 deletion mutants were created: Δ1 (aa residues 24 to 474), Δ2 (aa residues 
137 to 336), Δ3 (aa residues 348 to 683) and Δ4 (aa residues 674 to 949). The fragments were 
amplified from the full length molecule and cloned into the pCEP-Pu vector containing the BM40 
signal peptide sequence using the following oligonucleotides: Δ1: 5'-
CTAGCTAGCCCATCATCACCATCACCATGCTTCCAGTACTAGCCTC-3' containing the NheI 
site and His sequence; 5'-ATAGTTTAGCGGCCGCTCAGAGGTTGAGCTCCAGGAG-3' 
containing the NotI site; Δ2: 5'-
CTAGCTAGCCCCATCATCACCATCACCATCCAATCCCTGAGCCTGCA-3' containing the 
NheI site and His sequence; 5'-ATAGTTTAGCGGCCGCTCATTTGGTGTCCACATCGGC-3' 
containing the NotI site; Δ3: 5'-
GCAACAGCTGTCCATCATCACCATCACCATGGGACCAATGGCAGTCTGGTG-3' 
containing the pshAI site and the His sequence; 5'-CGGGATCCGTCGTGGCTGGGCTCCAG-3' 
containing the BamHI site; Δ4: 5’-
GCTAGCCCATCATCACCATCACCATCCGGCAGAGCACCTGGAG-3’ containing the NheI 
site and His sequence; 5’-ATAGTTTAGCGGCCGCTCATCAGGTCTTAAACATCAGG-3’ 
containing the NotI site. In addition, the MMRN2 or Δ2 cDNA were sub-cloned into 
pcDNA3.1/Myc-His vector by Hind III and Bam HI restriction. RNA was extracted from tumor 
frozen sections with the Trizol reagent (Invitrogen, Milan, Italy)., and reverse transcription 
performed using AMV-RT and exanucleotides (Promega, Milan, Italy). Real-time PCRs were 
carried out using the iQ™ SYBR® Green Supermix (Bio-Rad, Hercules, CA, USA) using the 
following oligonucleotides: GAPDH 5′-GAGAGACCCTCACTGCTG-3′, 5′-
GATGGTACATGACAAGGTGC-3′; HIF- 1α 5′-CAGAGCAGGAAAAGGAGTCA-3′, 5′-
AGTAGCTGCATGATCGTCTG-3′; The primer efficiency was ~100%, thus the comparative Ct 
method (2−ΔΔCt) was applied for the analyses. 
5.4  Cell transfection, expression and purification of recombinant proteins.  
293-EBNA cells were transfected by electroporation with the different pCEP-Pu constructs and 
selected in the presence of 0,5 µg/ml of puromycin and 250 µg/ml of G418. Positive clones were 
isolated and the expression analyzed by Western blotting. Confluent 293-EBNA cells were then 
incubated in serum-free medium for 48 hours, the media were collected and equilibrated with a 
buffer containing 50 mM NaH2PO4, 150 mM NaCl, 10 mM imidazole. The proteins were purified 
by means of the Ni-NTA resin and eluted with the elution buffer (50 mM NaH2PO4, 300 mM NaCl, 
250 mM imidazole). The different fractions were analyzed by SDS-PAGE followed by Coomassie 
blue staining. Protein fractions were then dialyzed against PBS and concentrated using polyethylene 
glycol (PEG). In addition, HT1080 cells were stably transfected by electroporation with the pcDNA 
constructs and selected in the presence of 600 µg/ml of G418. 
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5.5  Scratch test and cell migration assay. 
For the scratch test HUVEC cells were seeded in a 24-multiwell dish and allowed to grow until they 
reached confluency. Cells were then starved overnight and the day after a scratch wound across 
each well was made using a sterile pipet tip. Cells were washed to remove any loosely held cells 
and then incubated with medium containing 0,5 % serum in the presence of 5 µg/ml of purified 
MMRN2 or the equimolar concentrations (35nM) of Δ1, Δ2, Δ3 and Δ4 purified fragments, or type 
I collagen as a control. The open gap was then inspected over time with the microscope. Time 
course analysis was carried out by means of the LEICA AF6000 Imaging System (LEICA, Wetzlar, 
Germany). 
For the motility assay the transwell membranes carrying 8 µm pores were coated on the upper side 
with 5 µg/ml of MMRN2 or the equimolar concentrations (35nM) of Δ1 or Δ2 or Δ3 or Δ4 
fragments in the presence of 0,1M bicarbonate buffer pH 9,6 at 4°C overnight. Type I collagen was 
used as control. The next day the membranes were saturated with 1% BSA in PBS for 1 hour at 
room temperature. 1x10
5
 HUVEC cells were placed on the top layer of the permeable membrane in 
serum free M199 medium containing 0,1% BSA. In the bottom chamber VEGF-A was added to the 
medium as migratory stimulus at the concentration of 25 ng/ml. After 6 hours of migration cells 
were stained with Crystal violet for 30 minutes and counted. 
5.6  Cell viability and proliferation assay. 
HUVEC cells were incubated with 35 nM of MMRN2 or PBS for 24, 48 and 72 hours; in 
alternative the cells were challenged with MMRN2, collagen type I and the various deletion 
mutants for 48 hours and cell viability was analyzed. The MTT (3-(4,5-Dimethylthiazol- 2-yl)-2,5-
diphenyltetrazolium bromide, a tetrazole) reagent was added to the cells at a final concentration of 
0,3 mg/ml and incubated for 4 hours at 37°C in complete medium. The medium was discarded and 
the crystals solubilized with dimethyl sulfoxide (DMSO). The reduced form of the colorimetric 
substrate was then quantified at the spectrophotometer at 560 nm. Cell proliferation was assessed by 
culturing the mock and Δ2-transfected HT1080 cells in 96-well plates for 24, 48, 72 and 96 hours. 
Cells were stained with the Trypan blue solution (Sigma-Aldrich, Milan, Italy) and counted using a 
hematocytometer. 
5.7  TUNEL assay.  
The apoptotic rate was evaluated using the “in situ cell death detection kit, fluorescein” (Roche 
Diagnostics S.p.a, Milan, Italy) upon treatment of HUVEC cells with  5μg/mL recombinant 
MMRN2 or with the equimolar concentrations (35nM) of Δ1, Δ2, Δ3 and Δ4 purified fragments for 
48 hours, and the assay performed according to the manufacturer’s instructions. 
Lipopolysaccharides from Salmonella enteric Serotype enteritidis (LPS, Sigma-Aldrich, Milan, 
Italy) at the concentration of 100 ng/ml was used to induce HUVEC cell apoptosis. Briefly, the cells 
were fixed in 4% PFA for 20 minutes at room temperature, permeabilized for 2 minutes in freshly 
prepared permeabilization solution (sodium citrate 0,1%, Triton X-100 0,1%) at 4°C and incubated 
with the properly diluted enzyme solution for 1 hour at 37°C in humidified conditions.  
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The cells were mounted in Fluoroshield™ with DAPI (Sigma-Aldrich, Milan, Italy) and positive 
cells counted using a fluorescence microscope equipped with a 63X objective. The same protocol 
was used to score the apoptotic rate in HT1080 cells stably expressing the Δ2 fragment of MMRN2. 
 
5.8  Matrigel tube formation assay.  
The growth factor reduced Matrigel TM Matrix (BD Biosciences) was thawed at 4°C overnight; 40 
µl were quickly added to each well of a 96-multiwell dish using cold pipettes and was allowed to 
solidify for 30 min at 37°C. Once solid, 1x10
4
 HUVEC cells were resuspended in medium 
containing 0,5% serum and 5 µg/ml of purified MMRN2 or the equimolar concentrations (35nM) of 
Δ1, Δ2, Δ3 or Δ4 purified fragments, or type I collagen as a control and then seeded in each well. 
Time-course analyses was carried out for 12 hours by means of LEICA AF6000 Imaging System. 
Tube formation analysis was assessed with the Wimasis software 
5.9  3D in vitro angiogenesis assay. 
The 3D in vitro spheroid based angiogenesis tests were performed as previously described (Nakatsu 
MN. et al., 2007). Briefly, 4x10
2 
HUVEC cells per cytodex microcarrier were employed. ECs were 
incubated with the beads for 4 hours at 37°C, shaking every 20 minutes. After the incubation time, 
the coated beads were transferred into a flask containing complete medium and were incubated 
overnight at 37°C. The next day the coated beads were embedded into a fibrin gel with or without 
35nM of MMRN2 or the Δ1, Δ2, Δ3 and Δ4 purified fragments. To provide the required soluble 
factors to promote EC sprouting, NHDF cells were layered on top of the gel after resuspension in 
medium containing the purified fragments, in combination or not with VEGF-A (50 ng/ml). After 7 
days spheroids were fixed with 4% (w/v) paraformaldehyde for 15 minutes at room temperature and 
pictures were captured and analyzed by Image J software. 
5.10  ELISA test.  
 For the analysis of the binding of MMRN2 or Δ1, Δ2, Δ3 and Δ4 fragments with VEGF-A, 0.5 µg 
of the recombinant MMRN2 or the deletion mutants were used to coat the plates and BSA was used 
as a control. The wells were blocked with 2% BSA in PBS for 1 hour at room temperature and 
incubated with soluble VEGF-A (100 ng/well) in 0,2% BSA in PBS for 1 hour at 37°C. In other 
sets of experiments, the MMRN2-coated wells were incubated with soluble VEGF-B, VEGF-C, 
VEGF-D or PlGF. Binding was verified using the specific anti-cytokine antibodies; the ABTS 
substrate was added and absorbance at 405 nm detected with a spectrophotometer (TECAN, Milan, 
Italy). 
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5.11  Surface plasmon resonance tests. 
The affinity measurements were performed using a Biacore X100 biosensor (GE Healthcare) on a 
carboxymethyldextran-coated sensor chip (CM5) as previously described (Lorenzon E. et al., 2012). 
The purified MMRN2 (20 ng/ μl) or the Δ2 fragment (80 ng/μl) in Na acetate pH=4 were 
immobilized using amine coupling to a density of 3150 and 1770 resonance units (RU), 
respectively. VEGF-A165 and VEGF-A121, VEGF-B167, VEGF-C, VEGF-D and PlGF-1 were diluted 
in HBS-EP buffer (GE Healthcare) at different concentrations and injected over the sensor chip at a 
flow rate of 30 μL/min, with 60 seconds of analyte contact over the surface. In other sets of 
experiments when analyzing the interaction with VEGF-A145 and VEGF-A189, a NaCl 
concentration of 300 mM instead of 150 mM was employed. The kinetic parameters and 
dissociation constants (kD) were then determined using the BIAevaluation software. 
5.12  Deglycosylation and Tunicamicyn treatment. 
The cleavage of the MMRN2 carbohydrate chains was performed using the protein deglycosylation 
kit purchased from New England Biolabs (Beverly, MA) according to manufacturer’s instructions. 
Briefly, 50 µg of purified MMRN2 were incubated with deglycosylation mix under non denaturing 
or denaturing conditions for 4 hours at 37°C. The deglycosylated protein was used for the analysis 
of the MMRN2/VEGF-A interaction by ELISA test, as previously described. 
For the inhibition of N-linked glycosylation, 293-EBNA cell stably expressing MMRN2 or Δ2 
fragment were treated or not with 5 µg/ml of Tunicamycin every 2 hours for 24 hours in serum free 
medium. The non-glycosylated purified proteins were analyzed by Western blotting and used in the 
solid phase analysis to evaluate the binding with VEGF-A. 
5.13  Preparation of cell lysates and Western blot analysis. 
For the phosphorylation studies, HUVEC cells were treated with VEGF-A (15 ng/ml) with or 
without MMRN2 (5 µg/ml) or the equimolar concentration (35 nM) of the Δ2 purified fragment for 
different times. The cells were then lysed in cold buffer (1 mM CaCl2, 1 mM MgCl2, 15 mM Tris-
HCl pH 7.2, 150 mM NaCl, 1% TrytonX100, 0,1% SDS, 0,1% Na Deoxycholate) containing 25 
mM NaF, 1 mM DTT, 1 mM Na3VO4 and the protease inhibitors cocktail (Roche). For the 
Western blot analyses proteins were resolved in 4-20% Criterion Precast Gels (Bio-Rad 
Laboratories) and transferred onto Hybond-ECL nitrocellulose membranes (Amersham, GE-
Healthcare). Membranes were blocked with 5% BSA in TBS-T (100mM Tris-HCl pH 7.5, 0,9% 
NaCl, 0,1% Tween 20) and probed with the appropriate antibodies. The blots were finally 
developed using ECL (Western blotting detection, Amersham Biosciences) and exposed to X-ray 
films or acquired using the ChemiDoc Touch Imaging System (BIO RAD, Hercules, CA, USA). 
Alternatively the Odyssey infrared imaging system was used (Li-COR Biosciences, Lincoln, NE, 
USA). 
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5.14  Matrigel plug angiogenesis assay. 
Ten female BALB/c (Harlan S.r.l, Milan, Italy) mice were subcutaneously injected (0.5 ml/flank) 
with highly-concentrated (18 mg/ml) Matrigel containing PBS (five left flanks) or 50 ng/ml of b-
FGF and VEGF-A (five left flanks) or 50ng/ml of b-FGF and VEGF-A with 35 nM of MMRN2 or 
Δ2 (10 right flanks). Every other day the growth factors and the recombinant proteins were re-
injected into the plugs into a final volume of 100µl. After 10 days, the mice were sacrificed and the 
Matrigel plugs were excised. The plugs were divided in two parts, one half was fixed with formalin 
overnight, embedded in paraffin and sectioned onto slides stained with hematoxylin and eosin for 
histological observation. The remaining plugs were homogenized and the hemoglobin content was 
evaluated using the Drabkin reagent kit (Sigma-Aldrich, Milan, Italy), as previously described 
(Kang K. and Lim JS., 2012). 
 
5.15  In vivo tumor growth. 
Twenty female athymic nude mice (Harlan S.r.l, Milan, Italy) were injected with 1.5x10
6
 of 
HT1080 cells stably transfected with pcDNA3.1 vector carrying the MMRN2 or Δ2 coding 
sequence or with the empty vector. The left flanks of each mouse were injected with control cells, 
while the right flanks with cells expressing MMRN2 or Δ2. Tumor growth was monitored over time 
and tumor size measured with a caliper. The tumor volumes were calculated with the following 
formula: (xlengthxwidth2)/6. Tumor vascularity was imaged using AngioSense® 750EX 
(PerkinElmer). Anesthetized mice were retro-orbital injected with 2 nmol of AngioSense
®
 750EX 
in 100 µL of PBS and the fluorescence signal detected after 24 hour by IVIS Lumina instrument 
(Perkinelmer, Walthman, MA, USA). The mice were sacrificed and the tumors excised for 
immunofluorescence analysis. All the in vivo studies were approved by the Institutional Ethics 
Committee. 
5.16 Immunofluorescence analysis of ECs, tumors sections and whole mount 
retinas 
HUVEC cells were grown on cover glass slides placed in a 24 multi-well plate and treated with 
VEGF-A (10 ng/ml) and MMRN2 (5 µg/ml) or equimolar concentration (35nM) of Δ2 for 20 min at 
37°C and then fixed with 4% (w/v) paraformaldehyde for 15 minutes at room temperature. The 
cells were permeabilized with a PBS solution containing 1% BSA, 0,2% TRITON X-100 for 5 
minutes at room temperature, saturated with blocking buffer (PBS-2% BSA) for 1 hour and 
incubated overnight at 4°C with the α-VEGFR2 antibody. Next, the actin cytoskeleton and the 
nuclei were stained for 1 hour at room temperature with phalloidin and TO-PRO3, respectively. 
Slides were finally mounted in Mowiol containing 2,5% (w/v) of 1,4-diazabicyclo-(2,2,2)-octane 
(DABCO). The number of cells displaying VEGFR2 staining at the cell surface was evaluated by 
counting. Alternatively, HUVEC cells were grown on cover glasses, alone or in co-colture with 
HBVP (Human Brain Vascular Pericytes) at different ratio and incubated with α-human MMRN2 
and α-human SMA antibodies.  
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For immunofluorescence analyses with α-zona occludens (ZO-1), α-occludin (OCLN) and VE-
cadherin antibodies, HUVEC cells were transducted with MMRN2 siRNA or control adenoviral 
vectors and grown on cover glass slides until they reached the confluence. Then, the cells were 
fixed for 15 min at room temperature in 4% PFA diluted in PBS, washed 3 × 5 min, incubated in 
0.1% Triton X-100 (diluted in PBS) for 10 min at room temeprature, washed 3 × 2 min and then 
incubated in 50 mM Glycine in PBS for 10 min at room temperature. After washing 3 × 5 min, the 
coverslips were incubated with primary antibody solution (containing 1% BSA in PBS) for 1 hour 
at room temperature. Samples where then washed 3 × 10 min and the secondary antibodies were 
incubated in the same manner. Finally, coverslips where washed for 3 × 10 min and mounted using  
Mowiol containing 2,5% DABCO.  
For the immunofluorescence analyses of tumor sections, tumors were included in the Optimal 
Cutting Temperature compound (OCT) and frozen. For microvessel density analysis, 7 µm thick 
sections were obtained and stained with anti-mouse CD31.  
Images were acquired with a Leica TCS SP2 confocal system (Leica Microsystems Heidelberg, 
Mannheim, Germany), using the Leica Confocal Software (LCS) and vessel density was assessed 
by counting. 
For the retinal immunostainings, the retinas were isolated as previously described (Pitulescu M. et. 
al., 2010) from adult wild-type and knock-out C57BL/6 mice. The retinas were fixed in 4% PFA for 
2 hours at 4°C and saturated overnight at 4°C with the blocking buffer (PBS-1% BSA-0,3% 
TRITON X-100). The next day the specimens were incubated overnight at 4°C with the anti-
MMRN2 antibody and with mouse anti-SMA. After incubation, the retinas were washed with PBS 
5 times for 20 minutes, incubated with the specific secondary antibody for 2 hours at room 
temperature and washed 4 times for 20 minutes. Finally, the samples were mounted using Mowiol 
with 2,5% DABCO and the images were acquired with a confocal system (Leica Microsystems). 
5.17  Adhesion assay. 
For the adhesion assays 96 well-plates were coated with 10 µg/ml of MMRN2 or collagen type I at 
4°C. After an overnight incubation with the proteins, the solution was removed and the plate air-
dried at room temperature in a tissue-culture hood. Next, previously starved HBVP cells were 
resuspended in a medium containing 0.1% BSA and added to each well at a number of 2x10
5 
cells/ml. The plate was placed for 1 hour in the cell incubator at 37°C, next the cells were washed 
and stained with Crystal Violet. The extent of adhesion was assessed by measuring the Absorbance 
at 560 nm. 
To quantitatively monitor cell adhesion over time we exploited the xCELLigence Real Time dual 
plate Cell Analyzer (Roche). The 96 well E-Plates were pre-coated with 10 µg/ml of MMRN2 or 
collagen type I at 4°C overnight and HBVP cells were then seeded at a number of 5.0x10
4 
cells/well. Cell adhesion, measured as changes in impedance and recorded in arbitrary cell index 
(CI) units, was monitored every 5 minutes for 130 minutes. 
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5.18  Permeability assay. 
For this test, HUVEC cells (2x10
4
) were seeded on collagen type I-coated Transwell filters (1µm 
mm pore size, BD Biosciences) in 24-well dishes and cultured with 100 ml of complete Medium in 
the upper chamber and 600 ml of growth medium in the lower chamber. The cells were grown for 
five days without medium changes until they had reached confluence. Then, using sterile tweezers, 
each insert was picked up and the media gently removed. The inserts were washed with PBS and 
transferred to other fresh plates. Finally, 200 µl of growth medium containing FITC-Dextran 70 kD 
(1:100) were added to the upper chambers and 600µl of growth medium to the lower chamber. 
FITC-Dextran concentration was measured from the lower chambers by means of TECAN Infinity 
200 PRO instrument detecting the fluorescence at 535 nm. 
5.19  In vivo permeability: FITC-dextran perfusion assay. 
To analyze VEGF-induced acute permeability responses, 100µl of PBS or VEGF-A165 at a final 
concentration of 50 ng/ml were injected intradermally in the ear of wild-type or MMRN2 knock-out 
C57BL/6 mice, followed by retrorbital injection of 100µl of FITC-dextran (50 ng/ml in PBS). After 
30 minutes, mice were sacrificed, ear tissues were excised and fixed with 4% PFA. FITC-Dextran 
leakage from the vessels was assessed by immunofluoresce analyses from the fluorescent stereo-
microscope's images. 
5.20  Statistical analyses. 
Statistical analyses were performed using the Sigma Plot software. Student t-test for unpaired data 
was used to assess the probability of significant differences between two groups; for more than two 
groups, the ANOVA 1-way analysis of variance was used, according to the Bonferroni method. 
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6.1  Production and expression of four MMRN2 deletion mutants. 
In order to identify the active region of MMRN2 involved in the interaction with VEGF-A165 and in 
its anti-angiogenic effect, we firstly generated 4 deletion mutants. In particular we created the ∆1 
(aa residues 24 to 474), ∆2 (aa residues 137 to 336), ∆3 (aa residues 348 to 683) and ∆4 (aa residues 
674 to 949) deletion fragments. All these fragments were amplified from the full length molecule, 
cloned into the pCEP-Pu vector and expressed in 293-EBNA cells (Fig. 1A). Then, the expression 
of purified His-tagged deletion mutants was evaluated by Western blot analysis (Fig. 1B).  
 
Fig. 1: Schematic representation and analysis of the MMRN2 deletion mutants. (A) Schematic 
representation of the various MMRN2 deletion mutants (Δ1 to Δ4). The position number of the amino acid 
residues of the deletions is reported on top and excludes the first 24 residues of the signal peptide. The EMI 
domain (EMI), the coiled-coil region, the Arginine-rich domain (RR) and the gC1q domain (C1q) are 
indicated. (B) Western blot analysis of the His-tagged MMRN2 molecule and the various recombinant 




6.2  Analysis of the biological effects of the MMRN2 deletion mutants on ECs. 
Firstly, we verified if MMRN2 could affect the proliferation of HUVEC cells over time. For this 
purpose, HUVEC cells were incubated with 5µ/ml of MMRN2 for 24, 48 and 72 hours and we did 
not find significant changes in ECs’ viability (Fig. 2A). Thus, we decided to repeat the experiment 
only at 48 hours treating HUVEC cells with the equimolar concentration (35 nM) of MMRN2 and 
the various deletion mutants. In accordance with what found with the whole molecule, also the 
recombinant fragments did not affect the proliferation of ECs (Fig. 2B). Subsequently, we also 
assessed whether the deletion mutants, as the entire molecule, had no effect on EC apoptotic rate. 
To this end, the HUVEC cells were treated for 48 hours with 5 µg/ml of MMRN2 or with equimolar 
concentrations (35 nM) of the purified fragments or type I collagen used as a control. Following the 
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As shown in Fig. 2C, similarly to what obtained with the entire molecule, the MMRN2 deletion 
mutants did not alter the percentage of ECs undergoing apoptosis. 
 
 
Fig. 2: The MMRN2 deletion mutants do not alter proliferation or apoptotic rates of ECs. (A) Graph 
representing the % of cell viability of HUVEC cells challenged with 35 nM of MMRN2 or vehicle (PBS), 
following 24, 48 and 72 hours of incubation, as assessed by MTT assays. (B) Graph representing the % of 
cell viability of HUVEC cells challenged with equimolar concentrations (35 nM) of type I collagen (col I), 
MMRN2 or the deletion mutants (Δ1 to Δ4) performed after 48 hours of incubation. (C) Graph representing 
the % of apoptotic HUVEC cells challenged with equimolar concentrations of type I collagen (col I), 
MMRN2 or the deletion mutants (Δ1 to Δ4) as obtained by TUNEL assays performed after 48 hours of 
incubation; 100 ng/ml of LPS were used to induce apoptosis. P values were obtained with the ANOVA one 
way analysis of variance and graphs represent the mean ± SD obtained from at least three experiments. 
 
 
As carried out for the whole molecule, the purified deletion mutants were tested for their ability to 
inhibit EC migration. First we performed a scratch assay. To this end, HUVEC cells were seeded on 
24-multiwell plates, allowed to grow to confluency and then, a scratch wound across each well was 
made using a sterile pipet tip. Next, the cells were treated with 5 µg/ml of purified MMRN2 or with 
the equimolar concentrations (35 nM) of the four purified fragments and the EC movement across 
the area was monitored by time lapse analysis. After 6 hours, we found that, similarly to the effect 
exerted by the entire molecule, the Δ1 and Δ2 mutants were able to significantly inhibit the 
migration of HUVEC cells. On the contrary, as shown in Fig. 3A and Fig. 3B, Δ3 and Δ4 deletion 
mutants did not affect cell motility. These results were also corroborated by migration assays 
performed on transwells. In this case, 5 µg/ml of MMRN2 or equimolar concentrations (35 nM) of 
the Δ1, Δ2, Δ3, Δ4 purified fragments were coated on the upper side of transwell membranes. 
HUVEC cells were then placed on the top of the inserts' membrane and let migrate towards a 
VEGF-A165 stimulus at the concentration of 25 ng/ml. Also in this case, we found that only Δ1 and 
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Fig. 3: MMRN2 and its active mutants impair EC motility. (A) Representative images of the scratch test 
assay. HUVEC cells were treated with equimolar concentrations (35 nM) of MMRN2 and the various 
recombinant deletion mutants (Δ1 to Δ4); type I collagen was used as control and the front of cell migration 
at time zero (t=0) and after 6 hours (t=6) are highlighted; scale bar = 145 μm. (B) Graph representing the 
analysis of the scratch test expressed as the % of inhibition of EC’ migration respect to the collagen control; 
(*P ≤0.026). (C) Graph representing the migration on transwells of HUVEC cells challenged with equimolar 
concentrations (35 nM) of type I collagen (col I), MMRN2 or the deletion mutants (Δ1 to  Δ4); (*P ≤ 0.001). 
P values were obtained with the ANOVA one way analysis of variance and graphs represent the mean ± SD 
obtained from at least three experiments. 
 
 
6.3  Effect of the MMRN2 deletion mutants on ECs in 2D and 3D contexts. 
To further assess the influence of MMRN2 or its deletion mutants in affecting EC behavior, we 
carried out a tube formation assay on Matrigel. Indeed, the differentiation and reorganization of ECs 
to form tubules is one of key steps occurring during the angiogenic process. To verify the role of 
MMRN2 and its deletion mutants in this context, HUVEC cells were resuspended in a medium 
containing 5 µg/ml of MMRN2 or the equimolar concentrations (35 nM) of the purified fragments 
or type I collagen and then seeded on a pre-solidified matrigel matrix. The experiment was 
monitored over time by time-lapse microscopy and the analyses performed on the images captured 
at 12 hours of incubation. As shown in Fig. 4A to 4G, either the entire molecule or the Δ1 and Δ2 
deletion mutants strongly impaired the ability of ECs to form tubules on Matrigel. Conversely, 









Fig. 4: MMRN2 and its active mutants impair tubuligenesis on Matrigel. (A) Representative images of a 
matrigel tubulogenesis assay upon treatment of HUVEC cells with equimolar concentrations (35 nM) of the 
various recombinant molecules under analysis. Type I collagen was used as control; scale bar = 100 μm. (B) 
and (C) Graphs representing the evaluation of the number of tubes and total branching points as obtained 
from the experiment in A by means of with the Wimasis tube analysis software; (*P < 0.001).  (D), (E), (F) 
and (G), Graphs representing the analysis of respectively, the total  loops (*P < 0.001), the mean tube length 
(*P < 0.012), the mean loop area (*P < 0.001) and the mean loop perimeter (*P ≤ 0.001) obtained from the 
experiment reported in A and assessed by the Wimasis tube analysis software. P values were obtained with 
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Subsequently, to better resemble the physiological condition, the development of novel vessels was 
assessed in a 3D context following the treatment with MMRN2 or the various deletion mutants. To 
this end, we performed a spheroid-based 3D angiogenesis test, in which EC spheroids embedded in 
a fibrin gel and overlaid with Normal Human Dermal Fibrobalst (NHDF) were challenged with the 
recombinant molecules under analysis in combination or not with VEGF-A165 (50 ng/ml). As shown 
in Fig. 5A MMRN2 and the Δ1 and Δ2 mutants strongly hampered the sprouting of ECs. In 
particular, both the number and the length of the sprouts were significantly decreased when 
compared to those obtained with the control or following the treatment with Δ3 and Δ4. This effect 





Fig. 5: MMRN2 and its active mutants induce a striking reduction of the vessels' sprouts in a 3D 
context.  (A) Representative images of the spheroid angiogenesis assays performed following coating of 
HUVEC cells onto cytodex microcarriers end subsequently embedded into a fribrin gel overlaid with normal 
human dermal fibroblasts (NHDF) to induce EC sprouting. Spheroids were challenged with a 35 nM 
concentration of MMRN2 and the various deletion mutants in the presence or not of VEGF. Untreated 
spheroids served as negative control (CTRL); scale bar = 100 μm. (B) and (C) Graphs representing the 
evaluation of respectively the number and length of the sprouts of the experiment in D, as obtained with the 
Image J software; (*P < 0.001). P values were obtained with the ANOVA one way analysis of variance and 
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Accordingly, we found that the down-modulation of MMRN2 expression significantly increased 
vessels’ sprouting both in terms of number and the length of the sprouts (Fig. 6A to 6C). 
 
Fig. 6: The down-modulation of MMRN2 expression increased EC sprouting from a spheroid-based 
test. (A) Representative images of the spheroid angiogenesis assays obtained following coating of HUVEC 
cells transduced with the control or siMMRN2 adenoviral vectors. Fixed spheroids were stained with α-
CD31 (ECs) and SYTOX (nuclei), scale bar = 160 μm. (B) and (C) Graphs representing respectively the 
number (*P = 0.006) and the length (*P = 0.009) of the sprouts per spheroid, as assessed by means of the 
Volocity 3D software. P values were obtained using the Student’s t-test and the graphs represent the mean ± 
SD obtained from at least three independent experiments. 
 
 
6.4  The MMRN2 active mutant retains the capability to bind VEGF-A165. 
Given that we had previously demonstrated that the anti-angiogenic properties of MMRN2 relies, at 
least in part, on its ability to sequester the 165 isoform of VEGF-A, we wondered if the deletion 
mutants retained this binding capability. To address this question, we performed solid phase 
analyses in which 0.5 µg of the recombinant MMRN2 and its deletion fragments were immobilized 
on ELISA plates and incubated with soluble VEGF-A165  (100 ng/well). As shown in the Fig. 7A, 
only Δ1 and Δ2 mutants were able to interact to VEGF-A165, as opposed to the Δ3 and Δ4 mutants. 
Therefore, since in all experiments carried out, ∆2 mutant turned out to be the shortest fragment 
resembling the function of the whole molecule, we decided to employ only this mutant for the 
subsequent experiments. The interaction of VEGF-A165 with the Δ2 fragment was further confirmed 
by BIAcore analysis (Fig. 7B). However, the kD of the interaction (kD = 4.3x10
-7
, lower than that 
previously obtained with the MMRN2 kD = 5x10
-8
) was likely underestimated because the 
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Fig. 7: The Δ2 deletion mutant binds to VEGF-A165.  (A) Graph representing the solid phase analysis of 
the interaction of VEGF-A165 with the various deletion mutants indicating that the binding occurs through the 
region encompassed by the Δ2 fragment. BSA was used as negative control; (*P < 0.001). P values were 
obtained with the ANOVA one way analysis of variance and graphs represent the mean ± SD obtained from 
at least three independent experiments. (B) Sensogram expressed in resonance units (RU) of the surface 
plasmon resonance analysis of the interaction of VEGF-A165 with the Δ2 deletion mutant, the different 





6.5  The glycosylation of MMRN2 is required for an optimal interaction with 
VEGF-A165. 
Provided that MMRN2 is a glycosylated trimeric molecule able to sequester VEGF-A165, we 
wondered whether this direct binding occurred through the protein core or the carbohydrate chains. 
To address this question, we first performed solid phase binding studies in presence or not of 
heparin, a highly sulfated glycosaminoglycan with an high affinity for VEGF-A165. Interestingly, 
we found that the interaction of VEGF-A165 with MMRN2 was completely abolished in presence of 
heparin (Fig. 8A). This result suggested that the binding was dependent on the carbohydrate chains 
and that heparin could compete with the binding. To verify this hypothesis, we next removed the 
sugar chains from MMRN2 by means of a protein deglycosylation kit. As shown in Fig. 8B, we 
found that the interaction with VEGF-A165 was significantly impaired, despite the binding was not 
completely abolished. On the other hand, a complete abrogation of the binding was obtained when 
the cleavage of the carbohydrate chains was achieved under denaturing conditions. Despite this 
observation, under these conditions we could not rule out the possibility that this effect depended on 
the lack of the proper folding of the protein. An impaired binding was also observed using the entire 
molecule and the Δ2 deletion mutant produced under conditions that prevented protein 
glycosilation. For this purpose, MMRN2 and the Δ2 fragment was expressed in 293-EBNA cells in 
the presence of tunicamycin and the bands analyzed by Western blotting. The binding of VEGF-
A165 to the unglycosylated purified proteins were then analyzed through ELISA tests . As shown in 
Fig. 8C, the absence of carbohydrate chains almost completely abolished the interaction of VEGF-
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However, also in this case, the Western blot analysis indicated that the treatment with tunicamycin 
induced also a partial degradation of both recombinant molecules (Fig. 8D). Thus, we concluded 
that a contribution of the protein core to the interaction with VEGF-A165 could not be ruled out. 
 
Fig. 8: The binding of VEGF-A165 to MMRN2 occurs primarily through the carbohydrate chains (A) 
Graph representing the solid phase analysis of the interaction of VEGF-A165 with MMRN2 in the presence of 
heparin. BSA was used as negative control; (*P < 0.001). (B) Graph representing the solid phase analysis of 
the MMRN2/VEGF-A165 interaction following the cleavage of the carbohydrate chains with the Protein 
Deglycosylation Mix (degly. mix) under non denaturing or denaturing conditions (den. cond.); (*P < 0.003). 
(C) Graph representing the solid phase analysis of the interaction of MMRN2 and the Δ2 deletion mutant 
with VEGF-A165 with the employment of the recombinant molecules produced in the absence or in the 
presence of tunicamycin. The absence of the carbohydrate chains completely abolished the interaction; (*P < 
0.001). (D) Image of the Western blot analysis of recombinant MMRN2 and the Δ2 deletion mutant 
expressed in the presence or not of tunicamycin. P values were obtained with the ANOVA one way analysis 
of variance and graphs represent the mean ± SD obtained from at least three experiments. 
 
 
6.6  The binding of MMRN2 to other VEGF-A isoforms. 
To better investigate on the relative contribution of the carbohydrate chains versus the protein core 
of MMRN2 for the interaction with the cytokine, we assessed the capability of MMRN2 to interact 
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To this purpose, VEGF-A145 and VEGF-A189 displaying high affinity for heparin and VEGF-A121 
which lacks the heparin binding domain were interrogated for the binding to MMRN2. As shown in 
Fig. 9A, the VEGF-A121 isoform retained the capability to bind to MMRN2 (kD = 2.0×10
−7
 M), 
despite the interaction was much lower compared to that of VEGF-A165. Thus we concluded that the 
carbohydrate chains of MMRN2 play an important part in the interaction, despite not exclusive, and 
that the protein core could be also involved in the interaction. The important contribution of the 
carbohydrate chains is also suggested by the specific binding detected with VEGF-A145 and VEGF-
A189 (Fig. 9B). Indeed, both isoforms, characterized by a high affinity for heparin, displayed a good 
interaction with MMRN2, even higher than that observed with VEGF-A165 (kD = 2.7×10
−8
 M and 
kD = 3.0×10
−9 
M, respectively).  
 
Fig. 9: MMRN2 binds to different VEGF-A isoforms. (A) Dose response plot of the interaction of 
MMRN2 with VEGF-A165 and VEGF-A121, as obtained by surface plasmon resonance. (B) Dose response 




6.7  MMRN2 binds different VEGF family members. 
We have next evaluated whether the binding of MMRN2 was specific for VEGF-A165 or if the 
molecule could also interact with other members of the VEGF family. In particular, the binding of 
MMRN2 to VEGF-B167, VEGF-C and PlGF-1 was assessed by solid phase analyses. No detectable 
interaction was found in this experimental setting (Fig. 10A to 10C). The binding to VEGF-D was 
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Fig. 10: Analysis of the interaction of MMRN2 with VEGF-B, VEGF-C and PlGF-1 in solid phase 
analyses (A), (B), (C), Graphs representing the solid phase analyses of the interaction of MMRN2 with the 
VEGF-A family members VEGF-B167, VEGF-C and PlGF-1, respectively.  
 
However, specific interaction was detected through BIAcore analyses (Fig. 11A to 11E), despite it 
was much lower compared to that of VEGF-A165 (kD = 7.5×10
−7
 M, kD = 6.4×10
−7
 M, and kD = 
5.6×10
−7
 M). The interaction with VEGF-B167 could not be analyzed by plasmon resonance due to 
non-specific binding of the cytokine to the control flow cell. 
 
Fig. 11: MMRN2 binds to different VEGF family members (A), (B), (C). Sensograms reporting the 
binding of VEGF-C, VEGF-D and PlGF-1, as assessed by surface plasmon resonance. (D) Sensogram of the 
the binding at the concentration of 200nM of VEGF-A165, VEGF-C, VEGF-D and PlGF-1 to MMRN2, as 
assessed by surface plasmon resonance. (E) Dose response plot of the interaction of MMRN2 with VEGF-
A165, VEGF-C, VEGF-D and PlGF-1, as obtained by surface plasmon resonance. All the experiments were 
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6.8  MMRN2 and its active mutant affect VEGFR2 activation. 
We next aimed at better understanding the molecular mechanisms elicited by MMRN2 and its 
active deletion mutant. In our laboratory we had previously demonstrated that MMRN2 specifically 
blocked the VEGF-A-driven phosphorylation of VEGFR2 at Y1175 and that this inhibition was 
accompanied by a significant down-regulation of FAK phosphorylation. In the present study, we 
wondered whether MMRN2 affected other VEGFR2 tyrosine residues. In particular, given the 
influence of MMRN2 in EC migration, we analyzed the phosphorylation of residue Y1214 known 
to be involved in actin remodeling, vascular permeability and cell migration. To this end, HUVEC 
cells were challenged with MMRN2 (5 μg/ml) in presence or not of VEGF165 (15 ng/ml) for 2.5, 5 
and 10 minutes. As shown in Fig. 12A to 12C, we found that MMRN2 also inhibits the 
phosphorylation of VEGFR2 at Y1214 and induces a strong down-modulation of SAPK2/p38 
activation. Consistently, the treatment of HUVEC cells for 5 minutes with Δ2 deletion mutant (at 
the equimolar concentration of 35 nM) inhibited VEGFR2 phosphorylation at both Y1175 (Fig. 
12D and 12E) and Y1214 (Fig. 12F and 12G) residues. 
 
Fig. 12: MMRN2 and the Δ2 deletion mutant impair VEGFR2 activation. (A) Representative image of 
the Western blot analyses from the lysates of HUVEC cells challenged with MMRN2 in the presence or not 
of VEGF-A165 for different time points (2.5, 5 and 10 min, as indicated). Specific antibodies were used to 
detect total VEGFR2, pVGEFR2 Y1214, total (p38) and phosphorylated portion of SAPK2/p38 (p-p38). 
Actin was used as a normalizer of protein loading. (B) Graph reporting the quantification, expressed in 
arbitrary units (AI), of VEGFR2 phosphorylation at Y1214 from the Western blot analyses reported in A, as 
assessed with the Image J software; (*P < 0.002). (C) Graph reporting the quantification, expressed in 
arbitrary units (AI), of SAPK2/p38 phosphorylation from the Western blot analyses reported in A, as 
assessed with the Image J software; (*P < 0.001). (D) Representative image of the Western blot analyses 
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Total VEGFR2 (VEGFR2) and the phosphorylated portion at Y1175 (Y1175) were analyzed with specific 
antibodies. (E) Graph reporting the quantification, expressed in arbitrary units (AI), of VEGFR2 
phosphorylation at Y1175 from the Western blot analyses reported in D; (*P = 0.008). (F) Representative 
image of the Western blot analyses from the lysates of HUVEC cells challenged for 5 min with the Δ2 
deletion mutant in the presence or not of VEGF-A165. Total VEGFR2 (VEGFR2) and the phosphorylated 
portion at Y1214 (Y1214) were analyzed with specific antibodies. Vinculin was used as a normalizer of 
protein loading. (G) Graph reporting the quantification, expressed in arbitrary units (AI), of VEGFR2 
phosphorylation at Y1214 from the Western blot analyses reported in F; (*P = 0.003). P values were 
obtained using the Student’s t-test to assess the probability of significant differences between two groups and 




6.9  MMRN2 and its active mutant affect the redistribution of VEGFR2 to the 
EC plasma membrane in response to VEGF-A. 
Another important mechanism modulating EC function during the angiogenic process is the 
regulation of the availability of VEGFR2 receptor at the EC membrane. Thus, to assess whether 
MMRN2 or its active mutant could also affect this aspect, we treated HUVEC cells with 
recombinant MMNR2 (5 μg/ml) and an equimolar concentration (35 nM) of the Δ2 active fragment 
following or not stimulation with VEGF-A165 (10 ng/ml) for 20 minutes. The immunofluorescence 
analyses demonstrated that, in response to VEGF-A165 treatment, both molecules induced a 
significant impairment of  redistribution of VEGFR2 at the EC surface (Fig. 13A and 13B). 
 
Fig. 13: MMRN2 and the Δ2 deletion mutant impair the redistribution of VEFGR2 at the EC surface. 
(A) Representative images of the immunofluorescence analyses performed to assess VEGFR2 distribution in 
HUVEC cells challenged with MMRN2 or the Δ2 deletion mutant in the presence or not of VEGF-A165; 
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 (B) Graph representing the quantification of the number of cells displaying VEGFR2 staining at the cell 
surface from the experiment reported in H, at least 10 fields per condition were evaluated; (*P < 0.001). P 
values were obtained with the ANOVA one way analysis of variance and graphs represent the mean ± SD 
obtained from at least three experiments 
6.10  MMRN2 and its active mutant impair the angiogenic responses in in vivo 
experimental settings. 
Given the strong effect exerted by MMRN2 and its active deletion mutant in vitro, we hypothesized 
that they could also play an important anti-angiogenic role in vivo. To verify this hypothesis, we 
performed a Matrigel plug assay in which BALB/c mice were injected under the skin with Matrigel 
in presence of VEGF-A and basic FGF (bFGF) to induce angiogenesis, whereas  Matrigel 
containing PBS alone served as a negative control. Then, the plugs were treated or not with a 
concentration of, 35 nM of MMRN2 or the Δ2 recombinant protein to test whether the molecules 
could affect the development of blood vessels. After 10 days the mice were sacrificed and the 
excided plugs were analyzed. As shown in Fig. 14A and 14B, MMRN2 and its active deletion 
mutant reduced the hemoglobin content within Matrigel plugs, as assessed by means of the Drabkin 
reagent kit. The anti-angiogenic effect of both molecules was further confirmed by hematoxylin and 
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Fig. 14: MMRN2 and the Δ2 deletion mutant impair the development of blood vessels in the in vivo 
Matrigel plug assay. (A) Representative images of the plugs explanted from BALB/c mice and challenged 
with 35 nM of MMRN2 or Δ2 deletion mutant every other day for 10 days, in the presence or not of 50 
ng/ml VEGF-A165 and bFGF (V/F). Matrigel plugs were also treated with PBS as control. (B) Graph 
representing the spectrophotometric evaluation of the hemoglobin content within the plugs as assessed by 
means of the Drabkin’s reagent; (*P = 0.004). (C) Representative images of the hematoxylin and eosin 
staining of the Matrigel plugs upon treatment with 35 nM of MMRN2 or the Δ2 deletion mutant, in the 
presence of 50 ng/ ml VEGF-A165 and bFGF (V/F). The newly formed vessels within the plugs are 
indicated by an arrow; scale bar = 100 μm. (D) Graph representing the evaluation of the number of vessels 
within the plugs as assessed by counting on at least 10 fields for each point; (*P < 0.001). P values were 
obtained with the ANOVA one way analysis of variance and graphs represent the mean ± SD obtained from 
at least three experiments. 
 
 
6.11  MMRN2 and its active mutant halt the in vivo tumor growth and tumor 
angiogenesis. 
Next we verified whether the Δ2 active mutant could affect tumor growth and tumor associated 
angiogenesis, as demonstrated for the entire molecule (Lorenzon E. et al., 2012). For this purpose 
we generated HT-1080 cells ectopically expressing the Δ2 deletion mutant. Then, the Δ2 over-
expressing cells were implanted in the right flank of 10 nude mice, whereas in the left flank the 
mice were injected with mock transfected cells. In parallel, another group of mice were injected in 
the right flank with HT-1080 cells over-expressing MMRN2 and in the left flank with mock 
transfected cells. Tumor growth was monitored and the sizes measured. As shown in Fig. 15A and 
15B, in presence of both MMRN2 and the active fragment a strong inhibition of tumor growth was 
observed.  
 
Fig. 15: The over-expression of MMRN2 and the Δ2 deletion mutant is associated with a decreased 
tumor growth. (A) Graph reporting the measurements of the tumor volumes following the injection of 
mock-transfected HT1080 cells (CTRL, left flank) or MMRN2 over-expressing cells (MMRN2, right flank), 
as evaluated by means of a caliper; (*P < 0.001). (B) Graph reporting the measurements of the tumor 
volumes following the injection of mock-transfected HT1080 cells (CTRL, left flank) or Δ2 deletion over-
expressing cells (Δ2, right flank), as evaluated by means of a caliper; (*P < 0.001). P values were obtained 
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As demonstrated for the whole molecule, the anti-tumorigenic effect of Δ2 deletion mutant was 
likely indirect since the fragment did not alter the proliferation and the apoptotic rate of the tumor 
cells in vitro. In fact, the proliferation of Δ2 over-expressing cells at 24, 48, 72 and 96 hours 
following seeding on 96-well plates, was comparable to that of mock-transfected cells (Fig. 16A). 
Furthermore, also the apoptotic rate of HUVEC cells transfected with Δ2 deletion mutant construct 
was comparable to that of cells transfected with the empty vector, as assessed by TUNEL assay 
after 48 hours of incubation (Fig. 16B). 
 
Fig. 16: MMRN2 and the Δ2 deletion mutant did not affect the proliferation or apoptotic rate of 
HT1080 cells in vitro. (A) Graph reporting the growth curve of mock- or Δ2-transfected cells after 24, 48 72 
and 96 hours of incubation, as assessed by counting. (B) Graph reporting the similar % of apoptotic cells 
following transfection of HT1080 cells with the empty vector (CTRL) or Δ2 deletion mutant construct, as 
assessed by TUNEL assay. P values were obtained with the ANOVA one way analysis of variance and 
graphs represent the mean ± SD obtained from at least three experiments. 
 
Since the originated data indicated that the strong inhibition of tumor growth observed was not 
associated to a direct action of MMRN2 or its active mutant on cancer cells, we verified if this 
effect was due to a reduced intra-tumoral angiogenesis. In order to verify this hypothesis, we 
injected the animals with AngioSense 750EX and verified in vivo that both the whole molecule and 
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Fig. 17: The over-expression of MMRN2 and Δ2 deletion mutant is associated with an impaired intratumoral 
vascularization. (A). Representative image of the in vivo Imaging analyses following injection of 
AngioSense® 750EX in nude mice carrying control tumors (CTRL, left flank) or MMRN2 over-expressing 
tumors (MMRN2, right flank). Top image mouse photograph showing the decreased growth of the MMRN2-
ectopically expressing tumors, bottom image overlay of the photograph with the fluorescent signal of the 
AngioSense® 750EX probe. (B) Graph reporting the analysis of the fluorescent signals from mock (CTRL) 
and MMRN2 over-expressing tumors, as assessed with the dedicated software of the IVIS® Lumina 
instrument; (*P = 0.03). (C) Representative image of the in vivo Imaging analyses following injection of 
AngioSense® 750EX in nude mice carrying the control (CTRL, left flank) or the Δ2 deletion over-
expressing (Δ2, right flank) tumors. Top image mouse photograph showing the decreased tumor growth of 
Δ2-ectopically expressing tumors, bottom image overlay of the photograph with the fluorescent signal of the 
AngioSense® 750EX probe. (D) Graph reporting the analysis of the fluorescent signals from the mock 
(CTRL) and the Δ2 deletion over-expressing tumors, as assessed with the dedicated software of the IVIS® 
Lumina instrument; (*P = 0.004). P values were obtained using the Student’s t-test  and graphs represent the 
mean ± SD obtained from at least three experiments 
 
This finding was further confirmed by immunofluorescence analyses performed on sections 
obtained from the excised tumors. The cryosections were stained with the anti-mouse CD31 
monoclonal antibody to specifically detect the blood vessels and vessel density was assessed by 
counting five independent fields. As shown in Fig. 18A and 18B, a striking reduction of vessel 









Fig. 18: The MMRN2 and Δ2 over-expressing tumors display an impaired vascular density. (A) Representative 
images of the immunofluorescent analyses performed on tumor sections from mock-, MMRN2- and Δ2-
tumors (CTRL, MMRN2 and Δ2, respectively). Blood vessels were stained through an anti-CD31 antibody 
(α-CD31) and nuclei with TO-PRO; scale bar = 70 μm. (B) Graph reporting the analysis of the number of 
vessels per field as assessed by counting in at least 10 fields from the mock, MMRN2 and Δ2 tumor sections; 
(*P < 0.001). P values from  were obtained with the ANOVA one way analysis of variance and graphs 
represent the mean ± SD obtained from at least three experiments. 
 
Finally, to evaluate whether the decrease vessel density was associated with a modification of tumor 
microenvironment, such as the formation of hypoxic areas, we analyzed the expression of the 
Hypoxia-Inducible Factor-1 (HIF-1α), which is elicited when the oxygen content within the tissues 
decreases considerably. The qPCR analyses indicated that the MMRN2 and the Δ2 deletion over-
expressing tumors were characterized by an increased expression of HIF-1α and thus were likely 
more hypoxic compared to the control tumors (Fig.19).  
In conclusion, in the first part of this thesis we identify the region of MMRN2 responsible for the 
binding to VEGF-A165, demonstrate that it primarily involves the carbohydrate chains and verify the 
angiostatic activity both in vitro and in vivo. 
 
 
Fig. 19: The MMRN2 and Δ2 over-expressing tumors display an increased expression of HIF-1α. Graph 
reporting the qPCR analysis of HIF-1α expression in control (CTRL) or MMRN2/Δ2 deletion over-
expressing tumors (*P < 0.001). P values were obtained with the ANOVA one way analysis of variance and 
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6.12  Role of MMRN2 in vascular homeostasis.  
The data reported above further highlighted the key role of MMRN2 as an angiostatic molecule and 
prompted us to investigate another important aspect in which the protein is likely implicated: the 
vascular homeostasis. Indeed, given that MMRN2 is deposited in tight juxtaposition with ECs 
during the late stages of vascular development and is present in all the blood vessels in adulthood, 
we hypothesized that the molecule could also be involved in the regulation of blood vessel stability 
and homeostasis. Hence, the second part of my PhD project was dedicated to investigate this 
important aspect and the preliminary data that were generated are reported below.  
 
 
6.13  The deposition and organization of MMRN2 by ECs is boosted by the 
presence of pericytes.  
In order to assess how MMRN2 is secreted over-time by ECs and organized along the endothelium, 
HUVEC cells were seeded on coverslips and allowed to grow for 1, 3 and 5 days. 
We next performed the immunofluoresce analyses using a specific affinity purified anti-MMRN2 
polyclonal antibody that we have generated, which demonstrated that the deposition of MMRN2 
increased over time as well as its organization into fibrils (Fig. 20A). Interestingly, when the 
HUVEC cells were put in co-colture with human brain vascular pericytes (HBVP) we observed a 
strong increase of MMRN2 secretion and deposition compared to the condition in which the cells 
were seeded alone (Fig. 20B). 
 
Fig. 20: Pericytes positively affect the over time deposition of MMRN2 by ECs. (A) HUVEC cells were 
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The coverslips were stained with phalloidin (Ph) to highlight the actin cytoskeleton and the anti-MMRN2 
antibody; nuclei were stained with TO-PRO. (B) Immunofluorescence analysis of HUVEC cells in co-
culture with pericytes (HBVP) at different times points. Nuclei were stained with TO-PRO, pericytes were 
stained with the α-SMA antibody and MMRN2 with the specific affinity-purified polyclonal antibody. Scale 
bar = 50μm. 
 
 
To further verify if pericytes could influence MMRN2 deposition and organization, HUVEC cells 
were seeded alone or in co-colture with pericytes at different ratio. As shown in Fig. 21, not only 
the deposition of MMRN2 but also its organization into fibrils was striking enhanced in presence of 
an increasing number of pericytes in culture. Thus, we concluded that MMRN2 is strongly 
influenced by pericytes but the mechanisms responsible for this effect are still not clear for us. 
 
Fig. 21: An high concentration of pericytes boosts MMRN2 deposition and organization. 
Immunofluorescence analyses of HUVEC cells seeded, for 5 days, alone or in co-colture with pericytes at 
different ratios (5:1, 3:1, 2:1). The cells were stained with an α-SMA antibody to detect pericytes and the 
anti-MMRN2 affinity-purified polyclonal antibody. Nuclei were stained with TO-PRO. Scale bar = 35μm 
 
 
6.14  MMRN2 represents a substrate for pericytes’ adhesion. 
Next, given the putative role of pericytes in MMRN2 deposition we wondered if the molecule could 
represent an adhesion substrate for these cells. To address this question, we performed an adhesion 
assay in which human pericytes were seeded on plates coated with MMRN2 or collagen type I, used 
as a positive control. After the incubation, the cells were stained with crystal violet and the adhesion 
was assessed measuring the Absorbance at 560 nm (Fig. 22A and 22B). Our results indicated that 
the adhesion of HBVP to MMRN2 was comparable to that detected on collagen type I. This finding 
was further confirmed by monitoring over-time the adhesion of pericytes to collagen type I and 
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Fig. 22: MMRN2 represents a substrate for the adhesion of pericytes. (A) Graph representing the 
absorbance of Crystal Violet-stained cells following adhesion of HBVP plated on collagen type I (COLL I) 
or MMRN2. (B) Representative image of the adhesion assay reported in A (C) Evaluation of the pericyte 
adhesion to collagen type I or MMRN2 by means of the xCELLigence system. 
 
 
Interestingly, not only the secretion and organization of MMRN2 seems to be affected by pericytes, 
of which MMRN2 is a significant adhesion substrate, but it’s also likely that an initial deposition of 
MMRN2 could serve to achieve an optimal recruitment of pericytes. This hypothesis was suggested 
by the immunofluorescence analyses performed on the whole mounted retinas obtained from wild 
type (WT) and MMRN2
-/-
 C57BL/6 mice. In fact, as shown in Fig. 23A and 23B not only the 
retinas from the MMRN2 knock-out mice display an increased vascular density compared to that 








Fig. 23: MMRN2 KO mice display a significant impairment of the pericyte coverage of the retinal 
vessels. (A) Immunofluorescence analysis of whole mounted retinas from wild type (WT) and MMRN2
-/-
 
C57BL/6 mice stained with the anti-CD31 (vessels) and the anti-α-SMA (pericytes). (B) Graph representing 
the quantitative analysis of the vascular density (*P < 0.05), as obtained by means of the Image Tool 
software. (C) Graph representing the quantification of the co-localization of the anti-CD31 and the anti-a-
SMA staining obtained from the immunofluorescence analysis (*P < 0.05). P values were obtained using the 
Student’s t-test and graphs represent the mean ± SD obtained from at least three experiments. 
 
 
6.15  MMRN2 affects vascular permeability. 
Given the strategic deposition of MMRN2 in close proximity with the EC’ plasma membrane, we 
also questioned whether the protein could affect other important mechanisms characterizing the 
biology of ECs, such as those determining the formation and integrity of the EC’ monolayer.  
To address this hypotesis, we modulated the expression of MMRN2 in HUVEC cells and tested the 
effect on vascular permeability. To this end, HUVEC cells were transduced with MMRN2 siRNA 
(Ad siRNA) adenoviral or empty vector (Ad NEG), seeded on collagen type I-coated Transwell 
filters in 24-well dishes and grown for 5 days until they had reached confluency. Subsequently, the 
functionality of the EC barrier was assessed through the addition of FITC-Dextran on the top of the 
monolayer. The permeability of the monolayer in terms of FITC-Dextran leakage was measured by 
evaluating the presence of the compound at the wells’ bottom. As shown in Fig. 24, the down-
modulation of MMRN2 expression in ECs leads to a significant increase of vascular permeability in 












Fig. 24: MMRN2 is involved in the regulation of vascular permeability. Graph reporting the analysis of 
the % of the permeability of the HUVEC cells’ monolayers following transduction with the MMRN2 siRNA 
(Ad siRNA) adenoviral or the control vector (Ad NEG). Transwells’ membranes coated with collagen type I 
without ECs served as a control (CTRL). Its represents the 100% of vascular permeability respect to which 
was calculated the percentage of vascular permeability of the other two conditions. P values were obtained 
using the Student’s t-test and graphs represent the mean ± SD obtained from at least three experiments. 
 
 
This outcome led to the hypothesis that MMRN2 could be involved in the regulation of the 
formation of the cell-cell contacts. To verify this hypothesis we analyzed the distribution and 
expression of some proteins localized at the adherens and tight junctions following the down-
modulation of MMRN2 expression. Thus, HUVEC cells were transduced with the control or 
MMRN2 siRNA adenoviral vectors and the distribution/expression of the adherens junction protein 
VE-cadherin as well as the tight junction associated proteins zona-occludens-1 (ZO-1) and occludin 
(OCLN) was assessed by immunofluorescence. From these analyses we could conclude that the 
silencing of MMRN2 induced a significant alteration of OCLN and ZO-1 distribution along the 
tight junctions of ECs, whereas the distribution of VE-cadherin was not altered (Fig. 25A). 
Simultaneously, the expression of these molecules was analyzed by Western blotting under the 
same conditions. These analyses indicated that overall the total amount of OCLN and ZO-1 does 
not change upon modulation of MMRN2 expression (Fig. 25B). Thus, we concluded that the 
silencing of MMRN2 may compromise endothelial barrier function disturbing the localization but 
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Fig. 25: Analysis of adherens and tight junctions following the modulation of MMRN2 expression. (A) 
Immunofluorescence analysis of HUVEC cells transducted with MMRN2 siRNA (Ad siRNA) adenoviral or 
control vector (Ad NEG) and stained with specific antibodies detecting VE-cadherin, OCLN or ZO-1 (zona 
occludens-1). Nuclei were stained with TO-PRO. Scale bar = 35μm.  (B) Representative image of the 
Western blot analyses using lysates of HUVEC cells transducted with the MMRN2 siRNA (Ad siRNA) or 
control (Ad NEG) adenoviral vectors and grown till confluence was reached. Specific antibodies were used 
to detect VE-cadherin, OCLN and ZO-1. 
 
 
Finally, given the promising role of MMRN2 in the regulation of vascular permeability, we decided 
to corroborate these results in vivo. To this end, we employed the MMRN2 knockout mouse model 
and analyzed the vascular permeability in response to VEGF-A treatment. In particular, wild type 
and MMRN2
-/- 
mice were intradermically injected in the ear with 50 ng/ml of VEGF-A or the 
corresponding volume of vehicle.  Next, the mice received a retro-orbital injection of FITC-
Dextran. The mice were then sacrificed and the ears collected, fixed and analyzed by a stereo 
microscope. In accordance with the in vitro results, the MMRN2 deficient mice displayed an 
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Fig. 25: MMRN2 deficient mice display an increased vascular permeability. WT and MMRN2
-/-
 
C57BL/6 mice  were examined for vascular leakeage after intradermal injection of vehicle (PBS)  or VEGF 
(50 ng/ml) in mouse ear followed by retrorbital injection of 70-kD FITC-Dextran. The vessel leakage  
permeability (white arrows) was assessed through immunofluoresce analyses by means of a stereo 
microscope. 
Taken together, the preliminary results presented in the second part of this thesis suggest that 
MMRN2 may play an important role in the regulation of vascular homeostasis. Despite these 
evidences, further analyses are required to better define how MMRN2 regulates blood vessels' 
stability and permeability and to verify if this could influence tumor progression depending on the 
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The first part of my investigation was dedicated to further dissect the role of MMRN2 in the 
regulation of VEGF/VEGFR2 signaling pathway, the interaction with other members of the VEGF 
family and the effects on angiogenesis and tumor growth. The results obtained have been recently 
published by Oncotarget (Colladel R. et al., 2015). In particular, in this study, we corroborated the 
angiostatic function of MMRN2 and identified the active region responsible for these effects. 
Unlike EMILIN2, another member of the EDEN family, that simultaneously inhibits tumor growth 
by activating apoptosis (Mongiat M. et al., 2010; Marastoni S. et al., 2014) and induces the new 
vessel formation (Mongiat M. et al., 2010), the localization and the function of MMRN2 is specific 
and well characterized. MMRN2 instead plays a negative role in new blood vessel development, 
primarily acting through the inhibition of EC motility. This effect depends, at least in part, on its 
binding to VEGF-A165, and the sequestration of the ligand, one of the major cytokines promoting 
angiogenesis, leads to a down-regulation of VEGFR2.  
 
This investigation led to the discovery of a discrete portion of the molecule named Δ2 and located 
in the central coiled-coil region of the glycoprotein. By means of in vitro and in vivo tests we 
demonstrated that this fragment recapitulated all the effects exerted by the entire molecule. These 
results were compelling and were corroborated in an wide number of tests, including migration, 
proliferation, TUNEL assays, tubuligenesis on matrigel, as well as spheroid-based tests.  
A further discovery from these analyses indicated that the binding of MMRN2 and its active 
fragment to VEGF-A165 primarily occurs through the carbohydrate chains, since their enzymatic 
removal partially halted the interaction. Nonetheless, these examinations indicated that also the 
protein core was involved in the interaction, despite with a minor contribution. This conclusion was 
principally drawn by two observations. First, a specific binding, even if lower compared to that of 
VEGF-A165, was as well detected with the VEGF-A121 isoform, which lacks the heparin binding 
domain. Second, while testing of the binding of MMRN2 to other VEGF-A isoforms, we found that 
the glycoprotein interacted also with VEGF-A145 and VEGF-A189. These two isoforms are 
characterized by a higher affinity for heparin (Vempati P. et al 2014) if compared to that of VEGF-
A165, and accordingly, their affinity of the binding to MMRN2 was higher than that detected for 
VEGF-A165.  
 
The BIAcore analyses in order to determine if the interaction was specific for VEGF-A and the 
relative isoforms or it could be extended to other family members, indicated that MMRN2 displays 
a specific binding also with VEGF-C, VEGF-D, and PlGF-1, despite the affinity was weaker 
compared to that of VEGF-A165. Given the major role of the carbohydrate chains of MMRN2 in the 
interaction with these growth factors, it is possible that the low binding affinity for VEGF-C, 
VEGF-D, and PlGF-1 may depend on a different arrangement of the basic residues involved in the 
interaction with the carbohydrates (Chiodelli P. et al., 2015). Thus, from these analyses we may 
assume that MMRN2 could bind many cytokines halting angiogenesis and affecting the tumor 
microenvironment through different mechanisms. 
The striking biological effect obtained for Δ2 deletion mutant and the high number of putative 
glycosilated sites, 5 out of a total of 11 distributed along the whole molecule, led us to suppose that  
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An attempt to further dissect the functional region was pursued but none of the three smaller 
constructs generated could be secreted by 293-EBNA cells (data not shown). Since this fragment is 
characterized by alternated coiled-coil regions, it is possible that the smaller constructs did affect 
the local folding and prevent a proper trimerization process of the molecule, thus leading to protein 
degradation.  
 
Subsequently, my interest focused on better clarifying the mechanisms by which MMRN2 and its 
active mutant could impair EC motility. In our laboratory we had previously shown that MMRN2 
down-regulated the phosphorylation of VEGFR2 at Tyr1175 through the sequestration of VEGF-
A165 (Lorenzon E. et al., 2012). In this study we demonstrated that also Δ2 active mutant retains this 
function. Next, we further dissected the role of MMRN2 and its Δ2 deletion mutant in affecting 
VEGFR2 activation analyzing other important phosphorylation sites of the receptor. We found that, 
through the binding to VEGF-A165, both MMRN2 and the active fragment led to the down-
modulation of the phosphorylation of the receptor at Tyr1214 and, in turn, to a strong reduction of 
the activation of the SAPK2/p38 pathway. This result further reinforces our findings indicating that 
MMRN2 mostly impairs EC motility, in fact Tyr1214 is a key site whose phosphorylation regulates 
cell migration, actin remodeling and vascular permeability (Lamalice L. et al., 2004). 
 
Furthermore, in this study we also demonstrated an additional mechanism through which MMRN2 
negatively affects VEGFR2 activation. This involves the intracellular confinement of the receptor in 
the Golgi apparatus which is enhanced in the presence of MMRN2, thus reducing the availability of 
the receptor at the cell surface. It is known that the binding of VEGF-A to VEGFR2 at the plasma 
membrane induces the exit of intracellular VEGFR2 from the Golgi apparatus en route to the 
plasma membrane (Manickam V. et al., 2011). The treatment of ECs with MMRN2 or its Δ2 
deletion mutant did not lead to a detectable decrease of the total levels of expression of VEGFR2, as 
indicated by the Western blot analyses. Thus, it is likely that the impaired recruitment of the 
receptor at the cell surface may strictly depend on the sequestration of VEGF-A by MMRN2/Δ2, 
and thus on its decreased availability for receptor engagement. These findings further strengthen the 
role of MMRN2/Δ2 deletion mutant in negatively regulating EC activation by impinging on the 
VEGF-A/VEGFR2 signaling axis. 
 
It was recently published that the interaction of MMRN2 to CLEC14A, a single-pass 
transmembrane glycoprotein specifically expressed by ECs, induces the inhibition of sprouting 
angiogenesis and tumor growth (Noy PJ. et al., 2015). The authors claim that the inhibition of 
angiogenesis that we observed following over-expression of MMN2 may depend on the addition of 
MMRN2 in soluble form that induces the disruption of the interaction complex. On the contrary, in 
our view, MMRN2 functions as a homeostatic molecule that, once deposited, inhibits the sprouting 
of new vessels. This hypothesis is supported by the evidence that the molecule is physiologically 
expressed along all the vessels and it is not likely that once deposited it continues to support vessel 
sprouting. Thus, an inhibitory role is more probable. In fact, our published observations indicated 
that down-regulation of the MMRN2 by ECs increased their migration. In addition, here we 
demonstrated that the down-regulation of MMRN2 expression strongly increased the sprouting of 
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On the other end, one cannot exclude that at some stages of EC biology the molecule may exert also 
a stimulatory function and the different results obtained may depend on the different molecules used 
to generate the matrix spheroids have been embedded in. 
 
The promising results obtained in vitro, prompted us to evaluate the angiostatic function of 
MMRN2 and its functional deletion mutant in vivo, both in normal and in tumor angiogenesis. First, 
by means of plugs assays, we proved that both molecules strongly inhibited the development of 
blood vessels. Afterwards, we assessed the role of MMRN2 and its active mutant in tumor-
associated angiogenesis. The over-expression of MMRN2 and Δ2 mutant by HT-1080 cells induced 
a remarkable decrease of tumor growth when injected in nude mice. As previously observed for the 
whole molecule, we found that the Δ2 deletion mutant did not affect the proliferation or viability of 
HT-1080 cells in vitro, reinforcing the hypothesis that MMRN2 acts in an indirect way, likely 
impairing the vascular supply. Accordingly, the in vivo analyses carried out by means of the 
AngioSense
®
 750EX fluorescent imaging probe indicated that the over-expression of MMRN2 and 
the Δ2 deletion mutant negatively affected the development of blood vessels within the tumors. 
These data were corroborated by the analyses of the tumor sections; in fact, the MMRN2 and the Δ2 
over-expressing tumors displayed a strong impairment of vascular density suggesting that this effect 
was responsible for the reduced tumor growth observed. As a consequence, the increased intra-
tumoral hypoxia likely induced the expression of HIF-1α, which was particularly high in the Δ2 
mutant over-expressing tumors.  
 
In conclusion, taken together these findings provided additional evidences indicating that MMRN2 
exerts an angiostatic role. Furthermore in this study we identified the region responsible for the 
molecular and functional effects of this molecule. The expression of MMRN2 is altered in a wide 
number of tumor types (Soltermann A. et al., 2008; Shield-Artin KL. et al., 2012; Zanivan S. et al., 
2013) and this may significantly affect the development of the intratumoral vasculature. Given the 
negative role of MMRN2 in the regulation of tumor growth and tumor-associated angiogenesis it 
cannot be excluded that portions of the molecule may serve to develop potentially novel and 
powerful anti-angiogenic drugs to be employed for cancer treatment. Given that so far the anti-
angiogenic drugs developed have deluded the expectations, there is in fact the need to introduce 
new more efficacious tools in clinical practice. In this context, the ECM molecule or their matrix-
derived fragments (Bellotti D. et al., 2011) are a direct source of angiogenesis regulatory factors and 
MMRN2 may represent an important tool in this context. Besides the strategy of reducing the blood 
supply to block cancer growth, in the latest years a new approach has been taking credit. This 
strategy aims to readdress the aberrant tortuous and leaky vessels associated with the tumor to 
obtain an efficient vasculature (Sorensen AG. et al., 2012; Emblem KE. et al., 2013; Jain RK. 2014; 
Wong PP. et al., 2015). This would allow a more efficient delivery of chemotherapy within the 
tumors and thus a more efficacious treatment. 
In this context, there is so far no information as to whether an altered expression of MMRN2 can 
affect the efficiency of the vessels and vessel homeostasis.  
Thus, the second part of my investigation was dedicated to start shed light on this hypothesis and 





- 61 - 
 
First, this aspect was assayed in vitro where we observed that MMRN2 is secreted and deposited 
over time by ECs and that its organization progressively increased until fibrils were formed. 
Accordingly, our ex vivo experiments employing the aortic ring model indicated that, unlike mature 
vessels, the tip cells of new vessels departing from aortic rings are devoid of MMRN2 (unpublished 
not shown data) and this likely allows an efficient EC migration to form new blood vessels. 
Moreover, the analysis of MMRN2 expression in retinal vessels is in agreement with these findings; 
MMRN2 is almost absent in P1 and P2 stages of retinal development and its expression increases 
while vessel formation progresses. Interestingly, when the ECs were co-cultured in vitro with 
human pericytes, the deposition of MMRN2 strongly increased and was associated with the 
formation of  a well-defined network of fibrillar structures. This effect was striking strengthened in 
presence of an increasing percentage of pericytes in co-culture. The mechanism through which 
pericytes influence ECs, affecting MMRN2 production is still unclear. We are currently evaluating 
whether this effect requires a direct cell-cell contact between ECs and pericytes or, otherwise, the 
secretion of specific cytokines by pericytes which may act of ECs to boost MMRN2 secretion and 
organization.  
Not only the pericytes seem to affect MMRN2 expression but also the molecule is a substrate of 
adhesion for these cells and may also be required for their optimal recruitment, given that MMRN2 
knock-out mice display a significant decrease of pericytes’ coverage. In this scenario, an initial 
deposition of MMRN2 by ECs may serve as a substrate for the recruitment and consequent 
adhesion of pericytes, which, in turn, further boost the expression of the molecule leading to vessel 
stabilization. 
 
Consistent with a role of MMRN2 as a homeostatic molecule our preliminary results suggest that 
the glycoprotein stabilizes the EC barrier and plays a role in the proper formation of the ECs’ 
monolayer. In fact, the down-modulation of MMRN2 led to a significant increase of vascular 
permeability and this was associated with an impaired distribution of the tight junction molecules 
ZO-1 and OCCLUDIN, whereas VE-cadherin was not affected.  It is not yet known how MMRN2 
can impinge on the distribution of these molecules and if this depends on the impaired VEGFR2 
activation. Given that the expression of the ZO-1 and OCCLUDIN was not altered upon modulation 
of MMRN2 expression, it is likely that MMRN2 alters the mechanisms thought which the 
molecules are localized and confined to the tight junctions, possibly perturbing the environment at 
the EC surface. Interestingly, the molecular alterations seem to reflect on an impaired function not 
only in vitro, but also in vivo, since the MMRN2 knock-out mice displayed an increased vascular 
leakage. Thus, the presence of an efficient endothelial cell barrier seems to require a proper 
deposition of MMRN2, since its absence was not completely surrogated by other molecules in the 
murine model. 
 
Taken together, the results presented in this thesis reinforce the angiostatic role of MMRN2 and 
further dissect the mechanisms involved. Furthermore, we identified the region of the molecule 
responsible for these effects and provide preliminary evidences indicating that MMRN2 may 




- 62 - 
 
In conclusion, these results spur us to further shed light on the intricate mechanisms through which 
MMRN2 affects vessels’ homeostasis, thus representing a crucial molecule for the maintenance of 
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